Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Heart Failure

glucose, (beta-d)-isomer has been researched along with Heart Failure in 465 studies

Research

Studies (465)

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (1.94)	18.7374
1990's	1 (0.22)	18.2507
2000's	0 (0.00)	29.6817
2010's	85 (18.28)	24.3611
2020's	370 (79.57)	2.80

Authors

Authors	Studies
Epstein, JA; Feldman, AM; Rosenthal, N	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Hauske, S; Packer, M; Pocock, SJ; Zannad, F; Zeller, C	1
Anand, I; Anker, SD; Butler, J; Carson, P; Doehner, W; Ferreira, JP; Filippatos, G; Haass, M; Komajda, M; Miller, A; Packer, M; Pehrson, S; Pocock, SJ; Schnaidt, S; Schnee, JM; Teerlink, JR; Zannad, F; Zeller, C	1
Mendoza, VL; Punzalan, FER; Tumanan-Mendoza, BA	1
Hayashi, Y; Hsiao, YT; Ikegami, R; Katsuumi, G; Minamino, T; Nakao, M; Okuda, S; Shimizu, I; Soga, T; Suda, M; Yoshida, Y	1
Huynh, K	3
Achenbach, S; Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Schiffer, M; Schmieder, RE; Stabel, L	1
Karabulut, D; Karabulut, U; Keskin, K; Yiğit, E; Yiğit, Z	1
Aiwale, A; Ghag, S; Pawar, R; Trailokya, AA; Zalke, A; Zargar, AH	1
Bluhmki, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Lachin, JM; Ofstad, AP; Ohneberg, K; Salsali, A; Schmoor, C; Schumacher, M; Wanner, C; Zannad, F; Zinman, B	1
Slomski, A	5
Anker, SD; Butler, J; Sattar, N; Verma, S	1
Lo, KB; Mathew, RO; Rangaswami, J; Vaduganathan, M	1
Blair, HA	1
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A	4
Chan, YY; Chang, KC; Chang, SH; Hung, MJ; Lai, EC; Lin, SJ; Shao, SC	1
Abu-Assi, E; Amat-Santos, IJ; Blas, SG; Cruz-Gonzalez, I; de la Torre Hernandez, JM; Diez-Gil, JL; Gheorge, L; Ibáñez, B; Iñiguez-Romo, A; Lopez-Otero, D; Melendo-Viu, M; Muñoz-Garcí, AJ; Nombela-Franco, L; Raposeiras-Roubín, S; Romaguera, R; Sánchez-Luna, JP; Sánchez-Recalde, Á	1
García, Á; Gil-Rojas, Y; Lasalvia, P	1
Bartuś, S; Budaj, A; Dąbrowski, M; Drożdż, J; Gellert, R; Grąbczewska, Z; Grzelakowska, K; Jaguszewski, MJ; Jankowski, P; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Leszek, P; Małyszko, J; Michalski, P; Mitkowski, P; Navarese, EP; Nessler, J; Niezgoda, P; Pawlaczyk, K; Siller-Matula, J; Stolarek, W; Stompór, T; Wolnik, B	1
Borlaug, BA; Chandra, L; Chaudhry, SP; Chow, CH; Clemson, BS; Fong, M; Gordon, RA; Joseph, SM; Kanwar, MK; Khan, SS; Khariton, Y; Khumri, T; Kitzman, DW; Kosiborod, MN; Lamba, S; Lewis, GD; Malik, AO; Nassif, ME; Pursley, M; Ryan, JJ; Shah, SJ; Sharma, K; Siraj, ES; Tang, F; Umpierrez, G; Windsor, SL	1
Hamaoka, T; Hirai, T; Inoue, O; Kato, T; Kawashiri, MA; Mukai, Y; Murai, H; Sakata, K; Sugimoto, H; Takamura, M; Takashima, S; Takata, S; Usui, S	1
Borlaug, BA; Burkhoff, D; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Videbæk, L	1
Anand, IS; Berg, DD; Chopra, V; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Langkilde, AM; Lindholm, D; McMurray, JJV; Morrow, DA; Nicolau, JC; O'Meara, E; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Welsh, P	1
Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C	1
Achenbach, S; Bosch, A; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Pietschner, R; Schiffer, M; Schmieder, RE; Striepe, K	1
Giannakoulas, G; Kotsa, K; Koufakis, T; Zebekakis, P	1
Bengtsson, O; Böhm, M; Butt, JH; de Boer, RA; Desai, AS; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD	1
Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Chopra, VK; Filippatos, G; Jamal Siddiqi, T; Januzzi, JL; Kaul, S; Packer, M; Pedro Ferreira, J; Peil, B; Piña, IL; Pocock, SJ; Ponikowski, P; Senni, M; Shah, SJ; Vedin, O; Verma, S; Zannad, F	1
Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V	2
Adamson, C; Bengtsson, O; Butt, JH; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lindholm, D; Maria Langkilde, A; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD	1
Lim, GB	3
Barbancho, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Lara, JP; López-Carmona, MD; López-Sampalo, A; Millán-Gómez, M; Osuna-Sánchez, J; Pérez-Belmonte, LM; Ricci, M; Sanz-Cánovas, J	1
Echouffo-Tcheugui, JB; Lewsey, SC; Weiss, RG	1
Chen, QY; Guan, X; Jiang, YN; Lai, TF; Li, L; Ren, FF; Xie, ZY	1
Anker, SD; Brueckmann, M; Butler, J; Dhingra, NK; Ferreira, JP; Filippatos, G; Januzzi, JL; Lam, CSP; Nordaby, M; Packer, M; Peil, B; Pocock, SJ; Sattar, N; Verma, S; Zannad, F	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Packer, M; Pocock, SJ; Schnee, J; Zannad, F; Zeller, C	1
Binder, H; Daiber, A; Gori, T; Jünger, C; Koeck, T; Lackner, KJ; Münzel, T; Prochaska, JH; Rapp, S; Schulz, A; Wild, PS	1
Anand, IS; Bengtsson, O; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Nicolau, JC; O'Meara, E; Ogunniyi, MO; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S	1
Bates, ER	1
Anker, SD; Butler, J; Ferreira, JP; Filippatos, G; Pocock, SJ; Siddiqi, TJ; Zannad, F	1
Packer, M; Zannad, F	2
de Sousa, C; Pinto, FJ	1
de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P	1
Ismail, TF; Pooni, RS	1
Bengtsson, O; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Simpson, J; Sjöstrand, M; Solomon, SD	1
Artola Arita, V; Rienstra, M; Van Veldhuisen, DJ	1
Badimón, JJ; Requena-Ibáñez, JA; Rodriguez-Cordero, A; Santos-Gallego, CG; Vargas-Delgado, AP	1
Jardine, MJ; O'Hara, DV	1
Gómez-Huelgas, R; Lara, JP; Miramontes-González, JP; Osuna-Sánchez, J; Pérez-Belmonte, LM	1
Balcı, C; Ismayilov, R	1
Balogh, DB; Barczi, A; Fekete, A; Fintha, A; Hodrea, J; Molnar, A; Saeed, A; Szabo, AJ; Wagner, LJ	1
Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K	1
Andersen, CF; Gustafsson, F; Højlund, K; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C; Videbæk, L	1
Angermann, CE; Biegus, J; Blatchford, JP; Borleffs, CJW; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Fu, M; Janssens, SP; Kiss, RG; Kosiborod, M; Ma, C; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Sakata, Y; Salsali, A; Schirmer, H; Schou, M; Schulze, PC; Spinarova, L; Teerlink, JR; Tromp, J; Volterrani, M; Voors, AA; Wranicz, JK; Zeymer, U; Zieroth, S	1
Zheng, H	1
Kiyakbaev, G; Kokhan, E; Medovchshikov, V	1
Seki, H; Watanabe, H; Yorozu, T	1
Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G	2
Miller, WL	1
Chen, S; Coronel, R; Hollmann, MW; Weber, NC; Zuurbier, CJ	1
Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B	1
Anker, SD; Butler, J; Ferreira, JP; Filippatos, G; Januzzi, JL; Packer, M; Pocock, S; Schueler, E; Steubl, D; Zannad, F; Zeller, C	1
Bers, DM; Bossuyt, J; Habibi, NR; Hegyi, B; Mira Hernandez, J; Shen, EY	1
Angermann, CE; Biegus, J; Blatchford, JP; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Kosiborod, MN; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Salsali, A; Teerlink, JR; Tromp, J; Voors, AA	1
Larkin, HD	1
Ebell, MH	1
Colivicchi, F; Gronda, E; Zuccalà, G	1
Adamson, C; Bengtsson, O; Damman, K; de Boer, RA; Docherty, KF; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vaduganathan, M; Verma, S	1
Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC	1
Stiefelhagen, P	1
Belohlávek, J; Bengtsson, O; Butt, JH; Chiang, CE; Dewan, P; Docherty, KF; Drożdż, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S	1
Bengtsson, O; Boulton, DW; Docherty, KF; Greasley, PJ; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE	1
Aimo, A; Barison, A; Bayes-Genis, A; Emdin, M; Panichella, G; Passino, C; Senni, M	1
Aylward, P; Bhatt, DL; Cahn, A; Dalby, AJ; Dellborg, M; Dimulescu, D; Furtado, RHM; Gause-Nilsson, I; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Oude Ophuis, AJM; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD	1
Ali, M; Andersen, CF; Ersbøll, MK; Faber, J; Forman, JL; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C	1
Benson, L; Cosentino, F; Dahlström, U; Ferrannini, G; Lund, LH; McMurray, JJV; Mellbin, L; Savarese, G; Thorvaldsen, T	1
Facharztmagazine, R	1
Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Sumin, M; Udell, JA; Vedin, O; Zwiener, I	1
Fu, Z; Husain, M; Ilkayeva, O; Inzucchi, SE; Javaheri, A; Jones, P; Kosiborod, MN; Kwee, LC; Lanfear, DE; Margulies, KB; McGuire, DK; Mentz, RJ; Nassif, ME; Newgard, CB; Pitt, B; Scirica, BM; Selvaraj, S; Shah, SH; Windsor, SL	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Packer, M; Pocock, SJ; Siddiqi, TJ; Zannad, F; Zeller, C	1
Ananicheva, N; Andreev, D; Bogdanova, A; Charaya, K; Dyachuk, I; Kuzub, A; Mesitskaya, D; Poltavskaya, M; Shchekochikhin, D; Tarasenko, S	1
Bhattacharyya, D; Dhumale, S; Kar, A	1
Iliodromitis, EK; Triposkiadis, FK; Xanthopoulos, A	1
Amato, J	1
Greene, T; Heerspink, HJL; Inker, L	1
Anker, SD; Butler, J; Packer, M	1
Cosentino, F; Dhingra, NK; Pandey, AK; Verma, S	1
Anker, SD; Butler, J; Ferreira, JP; Filipattos, G; Kraus, BJ; Packer, M; Pocock, SJ; Ritter, I; Schüler, E; Zannad, F	1
Hao, Z; Zhang, Y	2
Fujiki, S; Imai, T; Inomata, T; Kashimura, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Shimabukuro, M; Suzuki, M; Tanaka, A; Uehara, H	1
Nishikawa, Y; Supakul, S; Takase, T; Teramura, M	1
Abdin, A; Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Gollop, ND; Iwata, T; Mahfoud, F; Packer, M; Pocock, SJ; Ponikowski, P; Wanner, C; Zannad, F	1
Sauer, AJ	1
Aimo, A; Bayes-Genis, A; Lupón, J	1
Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F	1
Krittayaphong, R; Permsuwan, U	2
Almengló, C; Durán, D; Eiras, S; Fernández, ÁL; Flores-Arias, MT; Fu, X; González-Juanatey, JR; Martínez-Cereijo, JM; Rodríguez-Mañero, M; Viñuela, JE	1
Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Leiter, LA; McGuire, DK; Mosenzon, O; Oyama, K; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD	1
Dural, İE; Ersoy, İ; Sarı, A	1
AlHummiany, B; Allwood-Spiers, S; Berry, C; Brooksbank, KJM; Campbell, RT; Chong, V; Coyle, L; Docherty, KF; Dreisbach, JG; Gillis, KA; Hall Barrientos, P; Jhund, PS; Kuehn, B; Labinjoh, C; Lang, NN; Lee, MMY; Lennie, V; Mangion, K; Mark, PB; McConnachie, A; McMurray, JJV; Murphy, CL; Petrie, CJ; Petrie, JR; Petrie, MC; Radjenovic, A; Roditi, G; Sattar, N; Sharma, K; Sourbron, S; Speirits, IA; Thompson, J; Welsh, P; Wetherall, K; Woodward, R; Wright, A	1
Calò, L; Cicogna, F; Ferrari, I; Monzo, L; Tota, C	1
Bengtsson, O; Biering-Sørensen, T; Butt, JH; DeFilippis, EM; Dewan, P; Docherty, KF; Fiuzat, M; Jhund, PS; Johansen, ND; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD; Vaduganathan, M	1
Gu, N; Liang, B	2
Frantz, S; Morbach, C; Nitschmann, S	1
Chen, M; Cheng, J; Ding, R; Gu, JF; Huang, JL; Tang, TJ; Wang, L; Wang, X; Zhou, P; Zuo, MY	1
Biegus, J; Ponikowski, P	1
MacDonald, TM; Mackenzie, IS	1
Bengtsson, O; De Boer, RA; Docherty, KF; Hammarstedt, A; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Little, DJ; Martinez, FA; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Welsh, P	1
Faber, J; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C	1
Nakajima, T; Node, K; Oyama, JI; Shimizu, T; Shiraki, A; Yokota, T	1
Ferry, A	1
Al Habeeb, W; Alcocer-Gamba, MA; Bachus, E; Belohlavek, J; Borleffs, CJW; Cabrera Honorio, JW; Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Dobreanu, D; Drozdz, J; Fang, JC; Han, Y; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Merkely, B; O'Meara, E; Petersson, M; Pham, VN; Saraiva, JFK; Shah, SJ; Solomon, SD; Tereshchenko, SN; Thierer, J; Vaduganathan, M; Vardeny, O; Verma, S; Wilderäng, U; Zaozerska, N	1
Bachus, E; Belohlávek, J; Butt, JH; Chiang, CE; Claggett, BL; de Boer, RA; Desai, AS; Drożdż, J; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Lindholm, D; Maria Langkilde, A; Martinez, F; McMurray, JJV; Merkely, B; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U	1
Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Peikert, A; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U	1
Bengtsson, O; Butt, JH; Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Docherty, KF; Gasparyan, SB; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kondo, T; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Petersson, M; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M	1
Anker, S; Butler, J; Harrington, J	1
Claggett, BL; Cunningham, JW; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McGrath, MM; McMurray, JJV; O'Meara, E; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U	1
Capece, U; Cinti, F; Cocchi, C; Crea, F; D'Amario, D; Ferraro, PM; Giaccari, A; Giordano, A; Gugliandolo, S; Guzzardi, MA; Indovina, L; Iozzo, P; Leccisotti, L; Lorusso, M; Mezza, T; Sorice, GP	1
Meißner, T	1
Bachir, N; Boukabous, A; Terki, A; Zaoui, N	1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Butler, J; Chopra, VK; Ferreira, JP; Filippatos, G; Giannetti, N; Iwata, T; Januzzi, JL; Kaul, S; Packer, M; Piña, IL; Pocock, SJ; Ponikowski, P; Rauch-Kröhnert, U; Senni, M; Shah, SJ; Siddiqi, TJ; Sumin, M; Verma, S; Zannad, F; Zhang, J	1
Chen, K; Liu, J; Qin, S; Qin, Y; Wang, C; Wu, X; Xiao, W; Yang, Y; Zhang, X	1
Fernández-Ruiz, I	2
Ji, Y; Sun, L; Wang, FF; Yan, XJ; Zhang, JL; Zhu, Y	1
Giri, S; Guha, A; Lanfear, DE; Ortiz, PA; Palaniyandi, SS; Pan, G; Roy, B; Thandavarayan, RA	1
Chen, F; Chen, K; Hwa, J; Jiang, K; Qian, J; Wang, D; Wang, H; Wu, Y; Xiang, Y; Xu, Y; Yang, B; Yu, Y; Zhou, C	1
Chang, R; Cui, B; Fan, Z; Hiram, R; Huang, C; Huang, H; Liu, T; Shi, S; Su, X; Tang, Y; Wu, G; Wu, J; Xiong, F; Yan, M; Zhang, W	1
Calabria, S; Cricelli, C; Dondi, L; Lapi, F; Maggioni, AP; Marconi, E; Martini, N; Medea, G; Parretti, D; Pedrini, A; Piccinni, C; Ronconi, G	1
Claggett, BL; de Boer, RA; Desai, AS; Hegde, SM; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M	1
Fudim, M; Van Spall, HGC	1
Ma, H; Ma, Y	1
Prázný, M	1
Adams, V; Augstein, A; Barthel, P; Goto, K; Jannasch, A; Labeit, S; Langner, E; Linke, A; Mangner, N; Männel, A; Schauer, A; Winzer, EB	1
Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE	1
Angermann, CE; Biegus, J; Blatchford, JP; Brueckmann, M; Collins, SP; Ferreira, JP; Kosiborod, MN; Nassif, ME; Ponikowski, P; Psotka, MA; Salsali, A; Teerlink, JR; Tromp, J; Voors, AA	1
Ageev, FT; Ametov, AS; Antsiferov, MB; Arutyunov, GP; Cherkashin, DV; Fomin, IV; Galstyan, GR; Galyavich, AS; Gilyarevskiy, SR; Glezer, MG; Ilyin, MV; Khalimov, IS; Khasanov, NR; Lebedeva, AI; Lopatin, YM; Nedogoda, SM; Salukhov, VV; Tarlovskaya, EI; Tereshchenko, SN; Villevalde, SV; Vinogradova, NG; Yakushin, SS; Zhirov, IV	1
Claggett, BL; de Boer, RA; Desai, AS; Docherty, K; Fang, J; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, F; Mc Causland, FR; McGrath, MM; McMurray, JJV; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Verma, S	1
Gutmann, C; Mayr, M; Zelniker, TA	1
Anker, SD; Brueckmann, M; Butler, J; Dhingra, NK; Filippatos, G; Januzzi, JL; Lam, CSP; Nordaby, M; Packer, M; Pedro Ferreira, J; Pfarr, E; Pocock, SJ; Sattar, N; Verma, S; Zannad, F	1
Güzel, T; İnci, Ü	1
Colombo, PC; Mebazaa, A; Solal, AC	1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; González-Juanatey, JR; Iwata, T; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Rocca, HPB; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Usman, MS; Verma, S; Vinereanu, D; Zannad, F; Zhang, J	1
Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Drozdz, J; Fang, JC; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; O'Meara, E; Petersson, M; Solomon, SD; Vaduganathan, M; Vardeny, O; Zieroth, S	1
Adeyeye, E; Khong, TK	1
Bayes-Genis, A; Núñez, J	1
Beernink, JM; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Laverman, GD; McMurray, JJV; Persson, F; Rossing, P; Sjöström, CD; Toto, RD; Wheeler, DC	1
Al-Mubarak, AA; Bomer, N; Damman, K; Heerspink, HJL; Schomburg, L; van der Meer, P; van Veldhuisen, DJ; Voors, AA; Weening, EH	1
Bég, SA; Dar, MS; Kaspers, S; Marx, N; Mattheus, M; Ofstad, AP; Wanner, C	1
Borleffs, CJW; Claggett, BL; de Boer, RA; Desai, AS; Dobreanu, D; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Solomon, SD; Vaduganathan, M; Vinh, PN	1
Melenovsky, V; Monzo, L	1
Kosiborod, MN; Selvaraj, S; Shah, SH	1
Butt, JH; McMurray, JJV; Solomon, SD	1
Angermann, CE; Biegus, J; Blatchford, JP; Collier, TJ; Collins, SP; Ferreira, JP; Gregson, J; Kosiborod, M; Nassif, ME; Pocock, SJ; Ponikowski, P; Psotka, MA; Teerlink, JR; Tromp, J; Voors, AA; Zeller, C	1
Al Thani, NA; Hasan, M; Yalcin, HC	1
Altiok, E; Böhm, M; Grebe, J; Keszei, AP; Korbinian Hartmann, NU; Lehrke, M; Marx, N; Rau, M; Thiele, K	1
Wiley, T; Williams, L	1
Desai, RJ; Everett, BM; Fu, EL; Levin, R; Patorno, E; Schneeweiss, S; Solomon, SD; Vaduganathan, M	1
Bachus, E; Booth, D; Chen, J; Comin-Colet, J; Davis, JA; De Boer, RA; McEwan, P; McMurray, JJV; Solomon, SD	1
Anand, I; Berg, DD; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Osmanska, J; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Welsh, P	1
Choi, YJ; Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lim, J; Na, JO; Park, JB; Rhee, TM	1
Lam-Chung, CE	1
Greenberg, B; Park, JJ	1
Mukherjee, D	1
Ohshiro, Y	1
Ishii, H; Iso, T; Kawakami, R; Kurabayashi, M; Matsui, H; Matsui, M; Yokoyama, T	1
Macari, S; Zannad, F	1
Boulton, DW; Cain, V; Dekkers, CCJ; Greasley, PJ; Heerspink, HJL; Sjöström, CD	1
Feng, B; Ma, X; Sun, K; Xu, G; Zhang, N; Zhou, Y	1
Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD	1
Anker, SD; Brueckmann, M; Butler, J; Filippatos, GS; George, J; Jamal, W; Kimura, K; Packer, M; Salsali, A; Schnee, J; Zannad, F; Zeller, C	2
Austin, B; Drazner, MH; Fong, MW; Givertz, MM; Gordon, RA; Husain, M; Inzucchi, SE; Jermyn, R; Katz, SD; Khariton, Y; Kosiborod, M; Lamba, S; Lanfear, DE; LaRue, SJ; Lindenfeld, J; Malone, M; Margulies, K; McGuire, DK; Mentz, RJ; Mutharasan, RK; Nassif, ME; Pitt, B; Pursley, M; Scirica, BM; Tang, F; Umpierrez, G; Windsor, SL	1
Fang, JC	1
Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN	1
Packer, M	3
Kato, ET; Sabatine, MS; Wiviott, SD	1
Elghazaly, H; Hajiev, S; Singh, P	1
Bhatt, DL; Braunwald, E; Verma, S	1
Butler, J; Vaduganathan, M	1
Bengtsson, O; Chiang, CE; DeMets, DL; Dutkiewicz-Piasecka, M; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S	1
Felker, GM	1
Bengtsson, O; DeMets, DL; Diez, M; Docherty, KF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; Niklasson, A; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S	1
Fukushima, A; Furihata, T; Kakutani, N; Katayama, T; Kinugawa, S; Maekawa, S; Matsumoto, J; Nakano, I; Nambu, H; Obata, Y; Saito, A; Shirakawa, R; Takada, S; Yamanashi, K; Yokota, T	1
Collins, SP; Tromp, J	1
DeVore, AD; Ezekowitz, JA; Felker, GM; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Mahaffey, KW; Sharma, A; Udell, JA; Wu, J	1
Hirose, M; Ibi, M; Ishida, N; Matsushita, N; Morino, Y; Saito, M; Sawa, Y; Taira, E	1
Ambrosio, G; Anker, S; Bauersachs, J; Chioncel, O; Coats, AJS; Cosentino, F; De Boer, RA; Filippatos, G; Hill, L; Huelsmann, M; Jhund, PS; Komajda, M; Lopatin, Y; Lund, LH; Lyon, A; Metra, M; Mullens, W; Petrie, MC; Piepoli, M; Polovina, MM; Ponikowski, P; Rosano, GMC; Sari, I; Seferović, J; Seferović, PM; Thum, T; Volterrani, M	1
Harrison, SL; Lane, DA; Lip, GYH	1
Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Inzucchi, SE; Marx, N; Mattheus, M; Ofstad, AP; Slawik, J; Verma, S; Wanner, C; Zinman, B	1
Verma, S	1
Docherty, KF; Jhund, PS; McMurray, JJV; Solomon, SD	1
Ablasser, K; Alber, H; Berger, R; Kaulfersch, C; Kolesnik, E; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Pferschy, PN; Reiter, C; Rieder, T; Saely, CH; Sailer, S; Siller-Matula, J; Sourij, H; Tripolt, NJ; Verheyen, N; von Lewinski, D; Weidinger, F; Zechner, PM	1
Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H	2
Beusekamp, JC; Boorsma, EM; Damman, K; Elvan, A; Heerspink, HJL; Smilde, TDJ; Swart, HP; van Eck, JWM; Voors, AA	1
Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ	1
Braam, B; Byrne, NJ; Darwesh, AM; Dyck, JRB; El-Kadi, AOS; Ferdaoussi, M; Jahng, JWS; Levasseur, JL; Light, PE; Maayah, ZH; Matsumura, N; Parajuli, N; Seubert, JM; Sweeney, G; Takahara, S; Verma, S; Vos, D; Young, ME	1
Advani, A; Batchu, SN; Connelly, KA; Desjardins, JF; Gilbert, RE; Kabir, G; Nghiem, L; Thai, K; Visram, A; Yerra, VG; Zhang, Y	1
Sullivan, K; Van Spall, HGC	1
Maier, LS; Mustroph, J; Trum, M; Wagner, S	1
de Boer, RA; Keefe, D; Kozlovski, P; Núñez, J; Proot, P; Wang, Y	1
Groenewegen, A; Rutten, FH	1
Casella, R; Casiraghi, C; Cazzaniga, A; Colombo, G	1
Borghi, C; Cicero, AFG	1
Dau, NQ; Peled, H	1
Mehra, MR; Vieira, JL	1
Docherty, KF; Jhund, PS; McMurray, JJV	1
Gu, N; Liang, B; Zhao, YX	1
Arnott, C; Neal, B	1
Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN	1
Bengtsson, O; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Vinh, PN	1
Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B; Zwiener, I	1
Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K	1
Dohi, K; Fujimoto, N; Fukuoka, S; Ishiyama, M; Ito, M; Moriwaki, K; Omori, T; Takeuchi, T	1
Altay, H; Cahn, A; Çavuşoğlu, Y; Celik, A; Demir, S; Kılıçaslan, B; Nalbantgil, S; Raz, I; Temizhan, A; Yıldırımtürk, Ö; Yılmaz, MB	1
Carballo, D; Carballo, S; Darbellay Farhoumand, P; Garin, N; Serratrice, J; Stirnemann, J	1
Ghosal, S; Sinha, B	1
Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I	1
Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A	1
Bagi, Z; Carrizzo, A; Ciccarelli, M; Falcão-Pires, I; Fülöp, GÁ; Hamdani, N; Herwig, M; Kolijn, D; Kovács, Á; Linthout, SV; Lódi, M; Maier, LS; Mügge, A; Pabel, S; Papp, Z; Reusch, PH; Sossalla, S; Tian, Y; Tschöpe, C; van Heerebeek, L; Vecchione, C; Zhazykbayeva, S	1
Ahmad, T; Bellumkonda, L; Butler, J; Collins, S; Cox, Z; Fleming, J; Griffin, M; Inzucchi, SE; Ivey-Miranda, J; Jacoby, D; Jeon, S; Mahoney, D; Maulion, C; Rao, VS; Riello, R; Siwakoti, K; Suda, N; Testani, JM; Turner, JM; Wilson, FP	1
Fitchett, DH; George, JT; Inzucchi, SE; Khunti, K; Mattheus, M; Ofstad, AP; Wanner, C; Zinman, B	1
Mareev, VY; Tsygankova, OV; Veretyuk, VV	1
Anand, IS; Bělohlávek, J; Bengtsson, O; Chopra, VK; DeMets, DL; Dewan, P; Dukát, A; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkely, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vinh, PN	1
Kim, HJ; Kim, JJ; Seong, JM; Sohn, HS	1
Anker, SD; Böhm, M; Brueckmann, M; Fitchett, D; George, JT; Kaspers, S; Mahfoud, F; Mancia, G; Marx, N; Ofstad, AP; Wanner, C; Zinman, B; Zwiener, I	1
Costantino, S; Paneni, F; Sciarretta, S	1
Patel, AB; Verma, A; Waikar, SS	1
Bengtsson, O; Claggett, BL; Desai, AS; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjostrand, M; Solomon, SD	1
Gazewood, JD; Tingen, J	1
Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Boulton, DW; Chopra, VK; de Boer, RA; DeMets, DL; Dewan, P; Docherty, KF; Dukát, A; Greasley, PJ; Howlett, JG; Inzucchi, SE; Jackson, AM; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S	1
Badimon, JJ; Garcia-Ropero, A; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; Santos-Gallego, CG; Sanz, J; Tunon, J; Vargas-Delgado, AP	1
Bergenheim, K; Böhm, M; Darlington, O; Docherty, KF; Jhund, PS; McEwan, P; McMurray, JJV; Petrie, MC; Qin, L	1
Raj, GM; Wyawahare, M	1
Bruun, NE; Brønd, JC; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L	1
Ahmad, T; Desai, NR	1
Basu, S; Hallow, KM; Yu, H	1
Lester, S; Van Klompenburg, E	1
Cowie, MR	1
Alenina, N; Bader, M; Crespo-Garcia, S; Dechend, R; Ebrahim, M; Golic, M; Grune, J; Haase, N; Herse, F; Heuser, A; Kintscher, U; Kräker, K; Luft, FC; Müller, DN; Reichhart, N; Strauß, O	1
Anand, IS; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Diez, M; Docherty, KF; Dukát, A; Ge, J; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Verma, S	1
Aschenbrenner, DS	2
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Jarcho, JA	1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Ofstad, AP; Packer, M; Pfarr, E; Pocock, SJ; Zannad, F	1
Anand, I; Bengtsson, O; Böhm, M; de Boer, RA; DeMets, DL; Desai, AS; Docherty, KF; Drozdz, J; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S	1
Katsiki, N; Kotsa, K; Kotsis, V	1
Cosentino, F; Savarese, G	1
De Caterina, R; Doria, V; Madonna, R; Minnucci, I; Pierdomenico, DS; Pucci, A	1
Anker, SD; Butler, J; Fonarow, GC; Handelsman, Y; Hernandez, AF; Khan, MS; Kosiborod, MN; McGuire, DK; McMurray, JJV; Rosenstock, J; Vaduganathan, M; Verma, S	1
Kosiborod, MN; McGuire, DK; Verma, S	1
George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC	1
Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD	1
Sotirakos, S	1
Liuzzo, G; Patrono, C	1
Anand, IS; Bengtsson, O; Böhm, M; Chopra, V; de Boer, RA; Desai, AS; Docherty, KF; Ge, J; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkley, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Shou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN	1
Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K	1
Nangaku, M	1
Anand, I; Anker, SD; Brueckmann, M; Butler, J; Carson, P; Doehner, W; Ferreira, JP; Filippatos, G; Haass, M; Jamal, W; Komajda, M; Miller, A; Packer, M; Pehrson, S; Pocock, SJ; Schnaidt, S; Teerlink, JR; Zannad, F; Zeller, C	1
Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD	1
Boulton, DW; Greasley, PJ; Hallow, KM; Penland, RC; Tang, W; Yu, H	1
Badimon, JJ; Garcia-Ropero, A; Santos-Gallego, CG	1
Brunton, S; Chilton, R	1
Cai, S; Connelly, K	1
Badimon, JJ; Flores-Umanzor, EJ; Fuster, V; Garcia-Ropero, A; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Vargas-Delgado, AP; Watanabe, S	1
Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB	1
Haynes, R; Judge, PK	1
Panchapakesan, U; Pollock, C	1
Butler, J; Greene, SJ; Khan, MS	1
Bengtsson, O; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE	1
Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F	1
Deswal, A; Palaskas, NL	1
Abascal, VM; Atallah-Lajam, F; Badimon, JJ; Contreras, JP; Fergus, I; Fuster, V; Garcia-Ropero, A; Lala, A; Macaluso, F; Mancini, D; Moreno, PR; Pinney, S; Requena-Ibanez, JA; Rodriguez-Cordero, A; Roque, M; Sabatel-Perez, F; Santos-Gallego, CG; Sanz, J; Sartori, S; Tamler, R; Vargas-Delgado, AP; Varley, C; Zafar, MU	1
Beusekamp, JC; Boorsma, EM; Damman, K; Danser, AHJ; Figarska, SM; Heerspink, HJL; Ter Maaten, JM; van der Meer, P; van Veldhuisen, DJ; Voors, AA	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Zannad, F; Zeller, C	1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Schnaidt, S; Schnee, JM; Senni, M; Seronde, MF; Shahzeb Khan, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zhang, J	1
Ibrahim, NE; Januzzi, JL	1
Node, K; Tanaka, A	2
Khunti, K	1
Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S	1
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC	1
Abraham, WT; Agostoni, P; Anker, SD; Brueckmann, M; Butler, J; Desai, AS; Filippatos, G; Fu, M; Gniot, J; Gullestad, L; Howlett, JG; Jamal, W; Krzysztof Wranicz, J; Lindenfeld, J; Nicholls, SJ; Nordaby, M; Peil, B; Ponikowski, P; Redon, J; Ritter, I; Salsali, A; Savarese, G; Schenkenberger, I; Silva-Cardoso, J; Störk, S; Ustyugova, A; Zeller, C	1
Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; de Boer, RA; Diez, M; Docherty, KF; Dukát, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S	1
Heerspink, HJL; Muskiet, MHA; van Raalte, DH	1
Bruun, NE; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Jensen, LT; Kistorp, C; Køber, L; Malik, ME; Møller, JE; Omar, M; Schou, M; Tuxen, C	1
Lang, NN; Lee, MM; Petrie, MC	1
Bengtsson, O; de Boer, RA; Desai, AS; Dewan, P; Docherty, KF; Drozdz, J; Hawkins, NM; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S	1
Martens, P; Mullens, W	2
Acharya, Y; Dahal, R; Mukherjee, D	1
Nabavizadeh, P; Steen, DL	1
Ali, M; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Möller, S; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, CD; Videbæk, L	1
Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Giannetti, N; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Packer, M; Peil, B; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Vedin, O; Verma, S; Zannad, F; Zeller, C	1
Bauersachs, J	1
Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Janssens, S; Packer, M; Pocock, SJ; Rocca, HB; Schnee, J; Tsutsui, H; Zannad, F; Zhang, J	1
Metra, M; Tomasoni, D	1
Kosiborod, M	1
Huang, J; Lin, X; Wang, S	1
Angoulvant, D; Fauchier, G; Fauchier, L	1
Bhattacharyya, D; Kar, A	1
Goswami, RM; Shanmuganathan, M	1
Esnault, VLM; Favre, G; Gérard, AO	1
Kumar, S; Sinha, S	1
Araújo, I; Cunha, GJL; Fonseca, C; Guerreiro, R; Henriques, C; Maltês, S; Presume, J; Rocha, BML; Rodrigues, C	1
Brodovicz, KG; Chung, WJ; Deruaz-Luyet, A; H-H Sheu, W; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Tan, EC; Yabe, D; Yasui, A	1
Bengtsson, O; Böhm, M; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kristensen, SL; Køber, L; Langkilde, AM; Lindholm, D; Martinez, MFA; McMurray, JJV; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Shen, L; Sjöstrand, M; Solomon, SD	1
Bhatt, K; Brush, J; Civitello, A; Gordon, R; Jermyn, R; Jonsson, O; Kosiborod, MN; Lamba, S; Lampert, B; Nassif, ME; Pelzel, J; Qintar, M; Shavelle, DM; Tang, F; Windsor, SL	1
Bengtsson, O; Butt, JH; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S	1
Spertus, JA	1
Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S	1
Austin, B; Fong, MW; Hartupee, J; Husain, M; Inzucchi, SE; Khariton, Y; Kosiborod, MN; LaRue, SJ; Malik, AO; McGuire, DK; Nassif, ME; Ogunniyi, MO; Pitt, B; Scirica, BM; Tang, F; Umpierrez, G; Wenger, NK; Windsor, SL	1
Anand, IS; Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD	1
Akinci, B	1
Abe, M; Fujikawa, K; Fujita, Y; Fukunami, M; Furukawa, Y; Hata, M; Kawahira, M; Kawai, T; Kawasaki, M; Kayama, K; Kikuchi, A; Morita, T; Nakamura, J; Sanada, S; Seo, M; Shintani, A; Tamaki, S; Tanabe, K; Taniuchi, S; Umayahara, Y; Watanabe, T; Yamada, T; Yamamoto, K	1
Drożdż, J; Gackowski, A; Gumprecht, J; Jankowska, EA; Kaźmierczak, J; Kukulski, T; Lelonek, M; Leszek, P; Nessler, J; Ponikowski, P; Rozentryt, P; Rubiś, P; Siniarski, A; Witkowski, A	1
Adler, AI; Douch, E; Dunning, L; Elliott, N	1
da Silva, AA; do Carmo, JM; Hall, JE; Hall, ME; Li, J; Li, X; Lu, Q; Mouton, A; Omoto, ACM; Qiu, Y; Wang, Z	1
Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Packer, M; Pocock, SJ; Sattar, N; Zannad, F	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Schueler, E; Steubl, D; Zannad, F	1
Špinar, J; Špinarová, L; Vítovec, J	1
Cai, Z; Cheng, H; Hu, X; Huang, H; Li, X; Liao, D; Tan, Z; Wang, C; Wang, Y; Wu, C; Wu, M; Xie, Y; Xu, F; Yin, K; Zeng, J; Zhao, W; Zhou, S; Zhou, X; Zhu, Y	1
Au Yeung, J; Khong, TK	1
Bengtsson, O; Butt, JH; Diez, M; Docherty, KF; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Ogunniyi, MO; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD	1
Bengtsson, O; Böhm, M; Chiang, CE; Desai, AS; Docherty, KF; Gasparyan, SB; Howlett, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S	1
Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA	1
Anyfanti, P; Sampani, E; Tsapas, A	1
Jensen, J; Møller, JE; Omar, M; Schou, M	2
Advani, A; Advani, SL; Batchu, SN; Connelly, KA; Kabir, G; Liu, Y; Siddiqi, FS; Yerra, VG	1
Beusekamp, JC; Boorsma, EM; Damman, K; Heerspink, HJL; Tromp, J; van der Meer, P; Voors, AA	1
Agbaje, OF; Coleman, R; George, JT; Grempler, R; Holman, RR; Hundertmark, MJ; Lamlum, H; Lee, J; Mahmod, M; Milton, JE; Neubauer, S; Niessen, HG; Rider, O; Rodgers, CT; Valkovič, L; Wicks, E	1
Chew, DS; Mark, DB	1
Goldhaber-Fiebert, JD; Heidenreich, PA; Khush, KK; Parizo, JT; Salomon, JA; Sandhu, AT; Spertus, JA	1
Claggett, B; de Boer, RA; DeMets, D; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Öhrn, F; Petersson, M; Shah, SJ; Solomon, SD; Wilderäng, U	1
Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Jamal, W; Januzzi, JL; Packer, M; Pocock, SJ; Zannad, F	1
Santos-Gallego, CG; Van Spall, HGC	1
Faber, J; Forman, JL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Schou, M; Tuxen, C	1
Anker, SD; Brueckmann, M; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Lam, CSP; Packer, M; Pfarr, E; Pocock, SJ; Sattar, N; Schnee, J; Sim, D; Tsutsui, H; Verma, S; Zannad, F	1
Cui, S; Dong, X; Gao, W; Liu, Y; Ren, L; Yin, X; Yu, L	1
Bayés-Genís, A; de la Espriella, R; Lorenzo, M; Miñana, G; Núñez, E; Núñez, G; Núñez, J; Santas, E	1
Lang, CC; Singh, JS; Struthers, AD	1
Jhund, PS; Lee, MMY; McMurray, JJV; Petrie, MC; Sattar, N	1
Borges, JI; Cora, N; Lymperopoulos, A; Sizova, A	1
Bellows, BK; Calvachi, P; Garan, AR; Gavin, MC; Hernandez, I; Isaza, N; Kazi, DS; Liu, CL; Raber, I; Shen, C	1
Bengtsson, O; Claggett, B; Docherty, KF; Ferreira, JP; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD	1
Atallah-Lajam, F; Badimon, JJ; Fuster, V; Giannarelli, C; Lala, A; Macaluso, F; Mancini, D; Requena-Ibáñez, JA; Rodriguez-Cordero, A; Santos-Gallego, CG; Sanz, J; Sartori, S; Vargas-Delgado, AP	1
Anker, SD; Asselbergs, F; Butler, J; Fitchett, D; Inzucchi, SE; Koudstaal, S; Lund, LH; Ofstad, AP; Savarese, G; Schrage, B; Uijl, A; Vedin, O; Wanner, C; Zannad, F; Zwiener, I	1
Chew, DP; Chong, W; De Pasquale, C; De Pasquale, CG; Hecker, T; Horsfall, M; Ilyas, F; Jones, L; Mangoni, AA; Selvanayagam, JB; Stranks, S; Swan, A; Tee, SL; Thomas, S; Wollaston, F	1
Abraham, WT; Anker, SD; Brueckmann, M; Hauske, S; Koitka-Weber, A; Lindenfeld, J; Peil, B; Pfarr, E; Ponikowski, P; Ritter, I; Salsali, A; Wanner, C	1
Ademi, Z; Kompa, AR; Liew, D; Owen, AJ; Savira, F; Tonkin, A; Wang, BH; Zomer, E; Zoungas, S	1
Asai, K; Hoshika, Y; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K	1
Carbone, S; daSilva-deAbreu, A; Lavie, CJ	1
Bhatt, DL; Cahn, A; Diaz, R; Gause-Nilsson, IAM; Goudev, A; Kuder, J; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Oyama, K; Park, KS; Raz, I; Sabatine, MS; Špinar, J; Wilding, JPH; Wiviott, SD	1
Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Solomon, SD; Stefánsson, BV; Toto, RD; Wheeler, DC	1
Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD	1
Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Wanner, C; Zannad, F; Zeller, C	1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure-Valenzuela, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Lam, CSP; Marx, N; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Schnaidt, S; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zeller, C; Zhang, J	1
Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH	1
Brand-Arzamendi, K; Garg, A; Liu, X; Quan, A; Shi, X; Singh, KK; Verma, S; Wen, XY; Yun, J	1
Tschöpe, D	1
Arya, N; Birkeland, KI; Bodegård, J; Cavender, MA; Fenici, P; Fu, AZ; Hammar, N; Holl, RW; Jørgensen, ME; Khunti, K; Kosiborod, M; Norhammar, A; Thuresson, M; Wilding, JP	1
Lehrke, M; Marx, N	2
Chilton, RJ	1
Verbrugge, FH	1
Dietl, A; Maack, C	1
Martens, P; Mullens, W; Verbrugge, FH	1
Anker, SD; Butler, J; Filippatos, G; Packer, M; Zannad, F	1
Anker, SD; Bernstein, RA; Brueckmann, M; Butler, J; Cheung, AK; Filippatos, G; George, JT; Green, JB; Hamo, CE; Januzzi, JL; Kaul, S; Lam, CSP; Lip, GYH; Marx, N; McCullough, PA; Mehta, CR; Pocock, SJ; Ponikowski, P; Rosenstock, J; Salsali, A; Sattar, N; Scirica, BM; Shah, SJ; Tsutsui, H; Verma, S; Wanner, C; Woerle, HJ; Zannad, F	1
Chien, FJ; Eisen, HJ; Kim, DH	1
Paneni, F	1
Butler, J; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B	1
Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV	1
Baig, F; Choy, AM; Lang, CC; McCrimmon, RJ; Mordi, IR; Mordi, NA; Singh, JS; Struthers, AD	1
Bjornstad, P; Cherney, DZI; Lovshin, JA; Lytvyn, Y; Udell, JA	1
Dobashi, S; Fujii, T; Hashimoto, H; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T	1
Kitzman, DW; Packer, M	1
Eckel, RH; Koh, KK; Lim, S	1
Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F	1
Abbate, A; Billingsley, HE; Buckley, LF; Buzzetti, R; Canada, JM; Carbone, S; Christopher, S; Dixon, DL; Kadariya, D; Markley, R; Medina de Chazal, H; Trankle, CR; Van Tassell, BW; Vo, C	1
Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B	1
Bansilal, S; Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IA; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JP; Wiviott, SD	1
Kulikov, NV; Obrezan, AG	1
Marx, N; Wanner, C	1
Katsiki, N; Triposkiadis, F	1
Bengel, P; Bollenberg, H; Fischer, T; Gummert, J; Hamdani, N; Hasenfuss, G; Kovács, Á; Maier, LS; Mustroph, J; Pabel, S; Renner, A; Schach, C; Sossalla, S; Streckfuss-Bömeke, K; Tirilomis, P; Tschöpe, C; Van Linthout, S; Wagner, S	1
Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA	1
Cannon, CP; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Kaspers, S; McGuire, DK; Pfarr, E; Sambevski, S; Scirica, BM; Zinman, B	1
Abascal, V; Atallah-Lajam, F; Badimon, JJ; Contreras, JP; Fergus, I; Fuster, V; Garcia-Ropero, A; Lala, A; Mancini, D; Moreno, P; Pinney, SP; Santos-Gallego, CG; Sanz, J; Tamler, R	1
Araújo, I; Campos, L; Cunha, GJL; Fonseca, C; Gomes, RV; Mendes, G; Morais, R; Rocha, BML	1
Böhm, M; Brueckmann, M; Ferreira, JP; Fitchett, D; George, J; Januzzi, J; Kaul, S; Ofstad, AP; Petrie, MC; Wanner, C; Zannad, F; Zeller, C	1
Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Januzzi, J; Lund, LH; Ofstad, AP; Sattar, N; Savarese, G; Verma, S; Wanner, C; Zeller, C; Zinman, B	1
McMurray, JJV; Verma, S	1
Bhatt, DL; Bonaca, MP; Cahn, A; Desai, AS; Furtado, RHM; Gause-Nilsson, I; Goto, S; Johanson, P; Johansson, PA; Kato, ET; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA	1
Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Furtado, RHM; Gause-Nilsson, IAM; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Raz, I; Ruff, CT; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA	1
Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD	2
Chang, CY; Chen, WY; Chen, YF; Dai, ZK; Jhuang, WJ; Jhuo, SJ; Lee, AS; Lee, HC; Liu, PL; Shiou, YL	1
Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Franklin, JM; Kulldorff, M; Najafzadeh, M; Patorno, E; Pawar, A; Sambevski, S; Santiago Ortiz, AJ; Schneeweiss, S	1
Badimon, JJ; Flores, E; Fuster, V; Garcia-Ropero, A; Hajjar, RJ; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Watanabe, S	1
Lehrke, M	1
Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC	1
de Boer, RA; Hillebrands, JL; Oberdorf-Maass, SU; Pavez Giani, MG; Schouten, EM; Silljé, HHW; van Goor, H; van Veldhuisen, DJ; Westenbrink, BD; Yurista, SR	1
Kondo, H; Takahashi, N	1
Bauersachs, J; Berliner, D	1
Polovina, MM; Seferović, JP; Seferović, PM	1
Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I	1
Kosiborod, M; Lam, CSP; Verma, S	1
Abraham, WT; Anker, SD; Brueckmann, M; Brun, M; Jamal, W; Lindenfeld, J; Macesic, H; Peil, B; Ponikowski, P; Salsali, A; Ustyugova, A; Zeller, C	1
Bruun, NE; Fosbøl, E; Frederiksen, PH; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L	1
WOLLENBERGER, A	1
Kihara, Y; Nakano, Y; Sairaku, A	1
Ding, W; Dong, M; Liao, Y; Liu, J; Liu, S; Liu, Y; Wang, R; Yan, D; Zhang, Y; Zheng, N	1
Kırat, T; Köse, N	1
Dohi, K; Fujii, E; Fujimoto, N; Ito, M; Moriwaki, K; Nakamori, S; Omori, T; Sato, Y; Takeuchi, T; Yamada, N	1
Peters, MN; Pollock, JS; Rajagopalan, S	1
Scheen, AJ	1
Cherney, DZ; Lytvyn, Y; Rajasekeran, H	1
Einecke, D	1
Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A	1
Laubner, K; Seufert, J	1
Murín, J	1
Ceriello, A; Genovese, S; Gronda, E; Mannucci, E	1
Albuquerque Rocha, N; McGuire, DK; Neeland, IJ; Pham, D	1
Cherney, DZ; Udell, JA	1
Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J	1
Bisping, E; Gasser, R; Grimm, M; Haas, T; Huber, MS; Pieske, B; Rainer, PP; Roessl, U; von Lewinski, D; Wasler, A; Wilhelm, B	1
MARTELLI, A	1
GALLINELLI, R	1
GOLAVSKII, VE	1
TELERMAN, M	1
LUSENA, M	1
ROTHLIN, E	1
MACREZ, C; MOUQUIN, M; PARIS, P; RENARD, J	1
Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L	1
Dai, RH; Li, Y; Luo, HM	1

Reviews

43 review(s) available for glucose, (beta-d)-isomer and Heart Failure

Article	Year
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:6 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2021
[Practical approach of dapagliflozin for the treatment of heart failure. Role of primary care physician]. Semergen, 2021, Volume: 47 Suppl 1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Physicians, Primary Care; Stroke Volume; Ventricular Function, Left	2021
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European heart journal, 2022, Feb-03, Volume: 43, Issue:5 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left	2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC. Heart failure, 2022, Volume: 10, Issue:2 Topics: Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Humans; Prospective Studies; Risk Assessment	2022
Direct cardiac effects of SGLT2 inhibitors. Cardiovascular diabetology, 2022, 03-18, Volume: 21, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Inflammation; Sodium; Sodium-Glucose Transporter 2 Inhibitors	2022
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart failure reviews, 2023, Volume: 28, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2023
Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review. Medicina (Kaunas, Lithuania), 2022, Jun-16, Volume: 58, Issue:6 Topics: Aged; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Glucosides; Heart Arrest; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2022
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. International journal of medical sciences, 2022, Volume: 19, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature medicine, 2022, Volume: 28, Issue:9 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Stroke Volume; Ventricular Function, Left	2022
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors. Journal of cardiovascular translational research, 2023, Volume: 16, Issue:5 Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2023
Comprehensive review of SGLT2 inhibitors' efficacy through their diuretic mode of action in diabetic patients. Frontiers in endocrinology, 2023, Volume: 14 Topics: Canagliflozin; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Observational Studies as Topic; Sodium-Glucose Transporter 2 Inhibitors	2023
Drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction: plain language summary of the EMPEROR-Reduced study. Future cardiology, 2023, Volume: 19, Issue:13 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Stroke Volume	2023
CaMKII and GLUT1 in heart failure and the role of gliflozins. Biochimica et biophysica acta. Molecular basis of disease, 2020, 06-01, Volume: 1866, Issue:6 Topics: Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Glucose Transporter Type 1; Glucosides; Heart Failure; Humans; Ketone Bodies; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2020
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice. Expert review of clinical pharmacology, 2020, Volume: 13, Issue:5 Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England), 2020, 09-19, Volume: 396, Issue:10254 Topics: Aged; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Body Mass Index; Case-Control Studies; Cause of Death; Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Patient Outcome Assessment; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation, 2020, 09-22, Volume: 142, Issue:12 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors	2020
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF. Circulation, 2020, 12-08, Volume: 142, Issue:23 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2020
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:3 Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2021
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. The American journal of cardiology, 2021, 01-01, Volume: 138 Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors	2021
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. Current opinion in nephrology and hypertension, 2021, Volume: 30, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan	2021
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European journal of heart failure, 2020, Volume: 22, Issue:12 Topics: Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
SGLT2 inhibitors in people with and without T2DM. Nature reviews. Endocrinology, 2021, Volume: 17, Issue:2 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2021
Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. Cardiovascular & hematological disorders drug targets, 2021, Volume: 21, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
An update on dapagliflozin for the treatment of heart failure. Drugs of today (Barcelona, Spain : 1998), 2021, Volume: 57, Issue:2 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2021
Diabetes Mellitus and Heart Failure. The American journal of medicine, 2017, Volume: 130, Issue:6S Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis	2017
Diabetes Mellitus and Heart Failure. The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis	2017
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. Current heart failure reports, 2017, Volume: 14, Issue:4 Topics: Benzhydryl Compounds; Blood Glucose; Diabetic Cardiomyopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2017
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Current heart failure reports, 2017, Volume: 14, Issue:4 Topics: Antioxidants; Benzhydryl Compounds; Calcium; Clonazepam; Glucosides; Heart Failure; Humans; Mitochondria, Heart; Oxidation-Reduction; Oxidative Stress; Ranolazine; Reactive Oxygen Species; Risk Factors; Thiazepines	2017
SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys. Current heart failure reports, 2017, Volume: 14, Issue:4 Topics: Benzhydryl Compounds; Disease Progression; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Natriuresis; Sodium-Glucose Transporter 1	2017
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. European journal of heart failure, 2017, Volume: 19, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2017
Pharmacologic Management for Heart Failure and Emerging Therapies. Current cardiology reports, 2017, 08-24, Volume: 19, Issue:10 Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan	2017
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation, 2017, Oct-24, Volume: 136, Issue:17 Topics: Benzhydryl Compounds; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. JACC. Heart failure, 2018, Volume: 6, Issue:8 Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan	2018
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
[Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment]. Kardiologiia, 2018, Volume: 58, Issue:7 Topics: Benzhydryl Compounds; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2018
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia, 2018, Volume: 61, Issue:10 Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2018
New drugs: big changes in conservative heart failure therapy? European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2019, 06-01, Volume: 55, Issue:Suppl 1 Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea	2019
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:11 Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss	2016
[Are some antidiabetic drugs also drugs useful for heart failure treatment?]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:4 Topics: Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Risk Factors	2016
Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular diabetology, 2016, 08-27, Volume: 15, Issue:1 Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Impact of empagliflozin in patients with diabetes and heart failure. Trends in cardiovascular medicine, 2017, Volume: 27, Issue:2 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2017
[Old and new positive inotropic drugs: problems and controversies]. Minerva cardioangiologica, 1984, Volume: 32, Issue:11 Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines	1984

Trials

141 trial(s) available for glucose, (beta-d)-isomer and Heart Failure

Article	Year
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 10-19, Volume: 144, Issue:16 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, 2021, Volume: 8, Issue:6 Topics: Aged; Benzhydryl Compounds; Female; Glucose; Glucosides; Heart Failure; Humans; Male; Middle Aged; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors	2021
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial. European journal of heart failure, 2022, Volume: 24, Issue:3 Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume; Transcatheter Aortic Valve Replacement; Treatment Outcome; Ventricular Function, Left	2022
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature medicine, 2021, Volume: 27, Issue:11 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Exercise; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires	2021
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. Circulation. Heart failure, 2022, Volume: 15, Issue:3 Topics: Benzhydryl Compounds; Blood Volume; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2022
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, Volume: 79, Issue:6 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States	2022
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovascular diabetology, 2021, 11-09, Volume: 20, Issue:1 Topics: 3-Hydroxybutyric Acid; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Up-Regulation; Vascular Stiffness	2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, 2022, Volume: 24, Issue:3 Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 01-18, Volume: 145, Issue:3 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Ventricular Function, Left	2022
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study. Journal of cardiovascular medicine (Hagerstown, Md.), 2022, 03-01, Volume: 23, Issue:3 Topics: Aged; Benzhydryl Compounds; Biological Specimen Banks; Diabetes Mellitus, Type 2; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Heart Failure; Heart Transplantation; Heart Ventricles; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left	2022
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC. Heart failure, 2022, Volume: 10, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European journal of heart failure, 2022, Volume: 24, Issue:6 Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left	2022
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:2 Topics: Benzhydryl Compounds; Ethnicity; Glucosides; Heart Failure; Humans; Minority Groups; Quality of Life; Stroke Volume	2022
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study. Geriatrics & gerontology international, 2022, Volume: 22, Issue:4 Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left	2022
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular diabetology, 2022, 02-27, Volume: 21, Issue:1 Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature medicine, 2022, Volume: 28, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2022
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 03-29, Volume: 79, Issue:12 Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Stroke Volume	2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 07-26, Volume: 146, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume; Treatment Outcome	2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 08-09, Volume: 146, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Ventricular Dysfunction, Left	2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, Volume: 65, Issue:7 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Annals of internal medicine, 2022, Volume: 175, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Frailty; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 05-24, Volume: 145, Issue:21 Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors	2022
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial. American heart journal, 2022, Volume: 250 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucose; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters; Ventricular Dysfunction, Left	2022
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of cardiac failure, 2022, Volume: 28, Issue:7 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2022
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American heart journal, 2022, Volume: 253 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. European journal of heart failure, 2022, Volume: 24, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open heart, 2022, Volume: 9, Issue:1 Topics: Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Pilot Projects; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss	2022
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial. Clinical research in cardiology : official journal of the German Cardiac Society, 2023, Volume: 112, Issue:1 Topics: Body Fluids; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2023
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 07-05, Volume: 80, Issue:1 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Treatment Outcome	2022
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European heart journal, 2022, 09-21, Volume: 43, Issue:36 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; Hyperuricemia; Male; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid	2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology, 2022, 09-01, Volume: 7, Issue:9 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans	2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. JACC. Heart failure, 2022, Volume: 10, Issue:8 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation, 2022, 09-27, Volume: 146, Issue:13 Topics: Benzhydryl Compounds; Biomarkers; Ferritins; Glucosides; Heart Failure; Hepcidins; Humans; Iron; Iron Deficiencies; Receptors, Erythropoietin; Receptors, Transferrin; Stroke Volume; Transferrins	2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2022
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 2022, 10-18, Volume: 146, Issue:16 Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume	2022
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation. Heart failure, 2022, Volume: 15, Issue:10 Topics: Aged; Aged, 80 and over; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Ventricular Function, Left	2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 10-04, Volume: 80, Issue:14 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left	2022
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovascular diabetology, 2022, 09-03, Volume: 21, Issue:1 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors	2022
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2022, 10-04, Volume: 146, Issue:14 Topics: Benzhydryl Compounds; Cardiomyopathies; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function, Left	2022
Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction. International heart journal, 2022, Sep-30, Volume: 63, Issue:5 Topics: Acute Kidney Injury; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hypotension; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovascular diabetology, 2022, 09-28, Volume: 21, Issue:1 Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Calcium; Connexin 43; Disease Models, Animal; Fura-2; Glucose; Glucosides; Heart Failure; Monocrotaline; Pulmonary Arterial Hypertension; Rats; Sodium; Ventricular Dysfunction, Right; Ventricular Remodeling	2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA cardiology, 2022, 12-01, Volume: 7, Issue:12 Topics: Aged; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left	2022
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. European heart journal, 2023, 01-01, Volume: 44, Issue:1 Topics: Benzhydryl Compounds; Furosemide; Glucosides; Heart Failure; Humans	2023
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA cardiology, 2023, 01-01, Volume: 8, Issue:1 Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Kidney; Male	2023
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nature medicine, 2022, Volume: 28, Issue:12 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature medicine, 2022, Volume: 28, Issue:12 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Function, Left	2022
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes care, 2023, 03-01, Volume: 46, Issue:3 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2023
The win ratio method in heart failure trials: lessons learnt from EMPULSE. European journal of heart failure, 2023, Volume: 25, Issue:5 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume	2023
Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study. Circulation. Cardiovascular imaging, 2023, Volume: 16, Issue:4 Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypoglycemic Agents	2023
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:12 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors	2019
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. European journal of heart failure, 2019, Volume: 21, Issue:10 Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2019
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation, 2019, 10-29, Volume: 140, Issue:18 Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2019
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine, 2019, 11-21, Volume: 381, Issue:21 Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2019
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure, 2019, Volume: 21, Issue:10 Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2019
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell metabolism, 2019, 11-05, Volume: 30, Issue:5 Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome	2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation, 2020, 01-14, Volume: 141, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebo Effect; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Ventricular Function, Left; Young Adult	2020
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation, 2020, 01-14, Volume: 141, Issue:2 Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Odds Ratio; Placebo Effect; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Ventricular Function, Left	2020
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. ESC heart failure, 2020, Volume: 7, Issue:1 Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Inpatients; Male; Registries; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2020
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. European journal of heart failure, 2020, Volume: 22, Issue:1 Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents	2020
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European heart journal, 2021, 03-31, Volume: 42, Issue:13 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2021
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. American heart journal, 2020, Volume: 221 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Ketone Bodies; Length of Stay; Mortality; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors	2020
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). European journal of heart failure, 2020, Volume: 22, Issue:4 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Treatment Outcome	2020
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. British journal of clinical pharmacology, 2020, Volume: 86, Issue:7 Topics: Anhydrides; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sorbitol; Treatment Outcome	2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA, 2020, 04-14, Volume: 323, Issue:14 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Risk Factors; Thrombolytic Therapy	2020
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes care, 2020, Volume: 43, Issue:6 Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling	2020
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation, 2020, 09-15, Volume: 142, Issue:11 Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged	2020
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. The Journal of clinical endocrinology and metabolism, 2020, 09-01, Volume: 105, Issue:9 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome	2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. European journal of heart failure, 2020, Volume: 22, Issue:7 Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2; Stroke Volume; Ventricular Function, Left	2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC. Heart failure, 2020, Volume: 8, Issue:10 Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Europe; Glucosides; Heart Failure; Humans; North America; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan	2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 09-15, Volume: 142, Issue:11 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume	2020
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American heart journal, 2020, Volume: 228 Topics: Accelerometry; Activities of Daily Living; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outcome Assessment, Health Care; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England journal of medicine, 2020, 10-08, Volume: 383, Issue:15 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation, 2020, 10-27, Volume: 142, Issue:17 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Glucosides; Heart Failure; Humans; Outpatients; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Clinical journal of the American Society of Nephrology : CJASN, 2020, 10-07, Volume: 15, Issue:10 Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2020
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation, 2021, 01-26, Volume: 143, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes care, 2020, Volume: 43, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome	2020
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. American heart journal, 2021, Volume: 232 Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss	2021
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Circulation. Heart failure, 2020, Volume: 13, Issue:12 Topics: Aged; Benzhydryl Compounds; Biomarkers; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Time Factors	2020
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 01-26, Volume: 77, Issue:3 Topics: Aged; Benzhydryl Compounds; Cardiac Imaging Techniques; Double-Blind Method; Exercise Test; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European journal of heart failure, 2021, Volume: 23, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Middle Aged; Sodium	2021
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. European journal of heart failure, 2020, Volume: 22, Issue:12 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Cardiovascular Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:4 Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:1 Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome	2021
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European heart journal, 2021, 02-11, Volume: 42, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2021
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:2 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left	2021
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European journal of heart failure, 2021, Volume: 23, Issue:4 Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Male; Pulmonary Disease, Chronic Obstructive; Stroke Volume	2021
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. JAMA cardiology, 2021, 07-01, Volume: 6, Issue:7 Topics: Aged; Benzhydryl Compounds; Echocardiography; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Organ Size; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2021
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovascular diabetology, 2021, 01-07, Volume: 20, Issue:1 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Pilot Projects; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure	2021
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European heart journal, 2021, 02-11, Volume: 42, Issue:6 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles	2021
[Empagliflozin and heart failure: the EMPEROR-Reduced trial]. Giornale italiano di cardiologia (2006), 2021, Volume: 22, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC. Heart failure, 2021, Volume: 9, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stroke Volume; Ventricular Function, Left	2021
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation, 2021, 04-27, Volume: 143, Issue:17 Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Pulmonary Artery; Sodium-Glucose Transporter 2 Inhibitors	2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 2021, Volume: 23, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left	2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA cardiology, 2021, 05-01, Volume: 6, Issue:5 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left	2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Lung; Quality of Life	2021
Effect of dapagliflozin on anaemia in DAPA-HF. European journal of heart failure, 2021, Volume: 23, Issue:4 Topics: Anemia; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume	2021
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circulation. Heart failure, 2021, Volume: 14, Issue:3 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; COVID-19; Creatinine; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Glucosides; Heart Failure; Hospitalization; Humans; Japan; Kidney; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2021
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 03-23, Volume: 77, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Volume; Diabetes Mellitus, Type 2; Diuretics; Drug Synergism; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hematocrit; Humans; Male; Natriuretic Peptides; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Water-Electrolyte Imbalance	2021
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. Journal of the American College of Cardiology, 2021, 03-23, Volume: 77, Issue:11 Topics: Aged; Benzhydryl Compounds; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Humans; Hyperkalemia; Kidney Function Tests; Male; Mineralocorticoid Receptor Antagonists; Outcome and Process Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Withholding Treatment	2021
EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction. Vnitrni lekarstvi, 2021,Winter, Volume: 67, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2021
Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients. Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:3 Topics: Anemia; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume	2022
Effect of dapagliflozin in patients with heart failure. Drug and therapeutics bulletin, 2021, Volume: 59, Issue:6 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA cardiology, 2021, 06-01, Volume: 6, Issue:6 Topics: Aged; Benzhydryl Compounds; Disease Progression; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology, 2021, 07-01, Volume: 6, Issue:7 Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC heart failure, 2021, Volume: 8, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life	2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European journal of heart failure, 2021, Volume: 23, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left	2021
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. European journal of heart failure, 2021, Volume: 23, Issue:9 Topics: Benzhydryl Compounds; Biomarkers; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume; Troponin T	2021
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation, 2021, Volume: 143, Issue:22 Topics: Benzhydryl Compounds; Double-Blind Method; Glucosides; Heart Failure; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European heart journal, 2021, 11-14, Volume: 42, Issue:43 Topics: Benzhydryl Compounds; Ethnicity; Glucosides; Heart Failure; Humans; Stroke Volume	2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA cardiology, 2021, 11-01, Volume: 6, Issue:11 Topics: Aged; Benzhydryl Compounds; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Survival Rate; Time Factors; Ventricular Function, Left	2021
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC. Heart failure, 2021, Volume: 9, Issue:8 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tropism	2021
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of cardiac failure, 2021, Volume: 27, Issue:8 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Prognosis; Risk Factors; Stroke Volume	2021
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC heart failure, 2021, Volume: 8, Issue:5 Topics: Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume	2021
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial. Journal of cardiac failure, 2022, Volume: 28, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Water-Electrolyte Balance	2022
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. European heart journal, 2022, 08-14, Volume: 43, Issue:31 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Overweight; Sodium-Glucose Transporter 2 Inhibitors	2022
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC. Heart failure, 2021, Volume: 9, Issue:11 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic	2021
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European heart journal, 2021, 09-21, Volume: 42, Issue:36 Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Death, Sudden, Cardiac; Glucosides; Heart Arrest; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left	2021
Empagliflozin and Major Renal Outcomes in Heart Failure. The New England journal of medicine, 2021, 10-14, Volume: 385, Issue:16 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 2021, 10-14, Volume: 385, Issue:16 Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo Circulation, 2017, Jul-18, Volume: 136, Issue:3 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Germany; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Internationality; Male; Middle Aged; Mortality; Norway; Registries; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Treatment Outcome; United Kingdom; United States	2017
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. European heart journal, 2018, 02-01, Volume: 39, Issue:5 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3 Topics: Adult; Benzhydryl Compounds; Blood Volume; Bumetanide; Diuresis; Diuretics; Drug Combinations; Drug Interactions; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Osmolar Concentration; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Water-Electrolyte Imbalance; Young Adult	2018
Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ open, 2017, Oct-16, Volume: 7, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Scotland; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Young Adult	2017
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER). Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:2 Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2018
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Benzhydryl Compounds; Body Mass Index; Cardiorespiratory Fitness; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Drug Interactions; Female; Glucosides; Heart; Heart Failure; Humans; Male; Middle Aged; Obesity; Oxygen Consumption; Pilot Projects; Respiratory System; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2018
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia, 2018, Volume: 61, Issue:8 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome	2018
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. American heart journal, 2018, Volume: 200 Topics: Aged; Benzhydryl Compounds; Cerebral Infarction; Diabetes Mellitus, Type 2; Diuresis; Drug Monitoring; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2019, 01-24, Volume: 380, Issue:4 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2019
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019, 03-12, Volume: 139, Issue:11 Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:1 Topics: Benzhydryl Compounds; Cardiovascular Agents; Double-Blind Method; Exercise Tolerance; Glucosides; Heart Failure; Humans; Magnetic Resonance Imaging; New York City; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Function, Right; Walk Test	2019
Empagliflozin Targeting the Real-World Heart Failure Population. Journal of cardiac failure, 2019, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus; Drug Delivery Systems; Female; Follow-Up Studies; Glucosides; Heart Failure; Humans; Male; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors	2019
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 05-28, Volume: 139, Issue:22 Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cause of Death; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 05-28, Volume: 139, Issue:22 Topics: Aged; Benzhydryl Compounds; Brain Ischemia; Cause of Death; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Time Factors; Treatment Outcome	2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European journal of heart failure, 2019, Volume: 21, Issue:5 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2019
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. European journal of heart failure, 2019, Volume: 21, Issue:7 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Exercise Tolerance; Female; Glucosides; Heart Failure; Humans; Male; Patient Reported Outcome Measures; Physical Functional Performance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2019
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials, 2019, Jun-21, Volume: 20, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European journal of heart failure, 2019, Volume: 21, Issue:11 Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prediabetic State; Reference Values; Registries; Treatment Outcome	2019
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovascular diabetology, 2016, Apr-04, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds	2016
[Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1995, Volume: 15, Issue:12 Topics: Adolescent; Adult; Aged; Astragalus propinquus; Cardiotonic Agents; Drugs, Chinese Herbal; Female; Gated Blood-Pool Imaging; Glucosides; Heart Failure; Humans; Injections, Intravenous; Male; Middle Aged; Saponins; Single-Blind Method; Triterpenes; Ventricular Function, Left	1995

Other Studies

282 other study(ies) available for glucose, (beta-d)-isomer and Heart Failure

Article	Year
Teasing the Immune System to Repair the Heart. The New England journal of medicine, 2020, 04-23, Volume: 382, Issue:17 Topics: Animals; Cell- and Tissue-Based Therapy; Disease Models, Animal; Heart Failure; Immune System; Leukocytes, Mononuclear; Mesenchymal Stem Cell Transplantation; Mice; Reperfusion Injury; Zymosan	2020
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. European journal of heart failure, 2021, Volume: 23, Issue:10 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2021
Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines. ESC heart failure, 2021, Volume: 8, Issue:6 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Philippines; Stroke Volume	2021
Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Scientific reports, 2021, 09-15, Volume: 11, Issue:1 Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cardiotonic Agents; Disease Management; Disease Models, Animal; Gene Expression Profiling; Glucosides; Heart Failure; Immunohistochemistry; Metabolome; Metabolomics; Mice; Microcirculation; Models, Biological; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left	2021
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved. Nature reviews. Cardiology, 2021, Volume: 18, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2021
Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction. Angiology, 2022, Volume: 73, Issue:4 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left	2022
Current Role of Dapagliflozin in Clinical Practice. The Journal of the Association of Physicians of India, 2021, Volume: 69, Issue:9 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC heart failure, 2021, Volume: 8, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2021
Study Projects Lifetime Benefits of Dapagliflozin in HFrEF. JAMA, 2021, Oct-05, Volume: 326, Issue:13 Topics: Benzhydryl Compounds; Cardiotonic Agents; Cause of Death; Clinical Trials, Phase III as Topic; Glucosides; Heart Failure; Humans; Life Expectancy; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume	2021
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European heart journal, 2022, 08-14, Volume: 43, Issue:31 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Sodium-Glucose Transporter 2	2022
Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation. Journal of the American College of Cardiology, 2021, 10-19, Volume: 78, Issue:16 Topics: Aged; Benzhydryl Compounds; Black or African American; Eligibility Determination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:3 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovascular diabetology, 2021, 10-23, Volume: 20, Issue:1 Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome	2021
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:4 Topics: Benzhydryl Compounds; Colombia; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology journal, 2023, Volume: 30, Issue:1 Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2023
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Muscles; Natriuretic Peptide, Brain; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System	2021
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 01-18, Volume: 145, Issue:3 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors. Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:3 Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Glucose; Glucosides; Heart Arrest; Heart Failure; Humans; Sodium; Stroke Volume; Ticks	2022
[Dapagliflozin in the prevention and treatment of heart failure]. Semergen, 2021, Volume: 47 Suppl 1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume; Ventricular Function, Left	2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation. Heart failure, 2021, Volume: 14, Issue:12 Topics: Aged; Atrial Fibrillation; Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left	2021
Dapagliflozin improves exercise capacity in HFpEF. Nature reviews. Cardiology, 2022, Volume: 19, Issue:1 Topics: Benzhydryl Compounds; Exercise Tolerance; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, Volume: 70, Issue:3 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Hospitalization; Humans; Insulins; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors	2022
SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease? The Journal of clinical investigation, 2021, 12-01, Volume: 131, Issue:23 Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Metabolic Diseases; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left	2021
Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:7 Topics: Animals; Apoptosis; Benzhydryl Compounds; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Glucose; Glucosides; Heart Failure; Mice; Sirtuin 1	2022
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. The lancet. Diabetes & endocrinology, 2022, Volume: 10, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Hypotension; Male; Stroke Volume	2022
In HFpEF, adding empagliflozin to usual care reduced a composite of CV death or HF hospitalization at a median 26 mo. Annals of internal medicine, 2022, Volume: 175, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume	2022
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. European journal of heart failure, 2022, Volume: 24, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes. Journal of cardiac failure, 2022, Volume: 28, Issue:4 Topics: Diabetes Mellitus, Type 2; Digoxin; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2022
Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence. European journal of heart failure, 2022, Volume: 24, Issue:3 Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Risk Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome	2022
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction. Clinical medicine (London, England), 2022, Volume: 22, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. European journal of heart failure, 2022, Volume: 24, Issue:3 Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2022
SGLT2 inhibitors may prevent diabetes. Nature reviews. Nephrology, 2022, Volume: 18, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2022
Reply to: Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, Volume: 70, Issue:5 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2022
Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, Volume: 70, Issue:5 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2022
SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PloS one, 2022, Volume: 17, Issue:2 Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heart Failure; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors	2022
Cardiovascular Benefits of Digoxin and Empagliflozin in Patients with Chronic Heart Failure: The DIG Trial Revisited. The American journal of medicine, 2022, Volume: 135, Issue:6 Topics: Benzhydryl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Glucosides; Heart Failure; Humans	2022
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection f European journal of heart failure, 2022, Volume: 24, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters	2022
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report. A&A practice, 2022, Mar-09, Volume: 16, Issue:3 Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis	2022
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes care, 2022, 05-01, Volume: 45, Issue:5 Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Insulins; Metformin; Prospective Studies; Stroke Volume	2022
SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor-Mediated Blunting of Blood Volume Redistribution: A Candidate Mechanism for Attenuating Cardiac Filling Pressures and Exercise Intolerance in Heart Failure-How Do the Data Stack up? Circulation. Heart failure, 2022, Volume: 15, Issue:3 Topics: Benzhydryl Compounds; Blood Volume; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2	2022
Benefit of empagliflozin in acute heart failure. Nature reviews. Cardiology, 2022, Volume: 19, Issue:5 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes research and clinical practice, 2022, Volume: 186 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Pulmonary Disease, Chronic Obstructive; Treatment Outcome	2022
Empagliflozin Reverses Late Na Circulation, 2022, 03-29, Volume: 145, Issue:13 Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Heart Failure; Humans; Mice; Myocytes, Cardiac; Stroke Volume	2022
FDA Expands Empagliflozin Heart Failure Indication. JAMA, 2022, 04-05, Volume: 327, Issue:13 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United States	2022
Empagliflozin Reduces Hospitalization for Heart Failure With Preserved Ejection Fraction, but Not Mortality Outcomes. American family physician, 2022, 04-01, Volume: 105, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume	2022
Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial". Circulation, 2022, 04-19, Volume: 145, Issue:16 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
In brief: Expanded heart failure indication for empagliflozin (Jardiance). The Medical letter on drugs and therapeutics, 2022, 04-18, Volume: 64, Issue:1648 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents	2022
MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin Improves Quality of Life in HFpEF. JAMA, 2022, 04-26, Volume: 327, Issue:16 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC. Heart failure, 2022, Volume: 10, Issue:5 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyponatremia; Sodium; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2022
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 09-13, Volume: 146, Issue:11 Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiomyopathies; Fatty Acids; Female; Glucosides; Heart Failure; Humans; Ketones; Ketosis; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left	2022
Dapagliflozin Safe and Effective for Heart Failure With Frailty. JAMA, 2022, 05-24, Volume: 327, Issue:20 Topics: Benzhydryl Compounds; Cardiovascular Agents; Frailty; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome	2022
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 2022, 05-26, Volume: 386, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 2022, 05-26, Volume: 386, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 2022, 05-26, Volume: 386, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine, 2022, 05-26, Volume: 386, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply. The New England journal of medicine, 2022, 05-26, Volume: 386, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. European heart journal, 2022, 08-14, Volume: 43, Issue:31 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Potassium; Sodium-Glucose Transporter 2 Inhibitors	2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European heart journal, 2022, 08-14, Volume: 43, Issue:31 Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Potassium; Stroke Volume; Ventricular Function, Left	2022
Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction. The Canadian journal of cardiology, 2022, Volume: 38, Issue:10 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number? Journal of the American College of Cardiology, 2022, 07-05, Volume: 80, Issue:1 Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions. European journal of heart failure, 2022, Volume: 24, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume	2022
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:5 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Thailand	2022
Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue-molecules and SGLT2i dapagliflozin. Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:16 Topics: Adipose Tissue; Benzhydryl Compounds; Endothelial Cells; Female; Glucosides; Heart Failure; Humans; Neutrophils; Obesity; Phenotype; Stroke Volume	2022
Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency. Echocardiography (Mount Kisco, N.Y.), 2022, Volume: 39, Issue:8 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Heart Ventricles; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left	2022
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2022, 07-26, Volume: 146, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Prediabetic State; Stroke Volume	2022
What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin? Journal of cardiovascular medicine (Hagerstown, Md.), 2022, 08-01, Volume: 23, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
[Empagliflozin in the treatment of heart failure with preserved ejection fraction]. Innere Medizin (Heidelberg, Germany), 2022, Volume: 63, Issue:7 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Liquiritin inhibits H Journal of food biochemistry, 2022, Volume: 46, Issue:10 Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Antioxidants; Catalase; Flavanones; Glucosides; Glutathione; Glutathione Reductase; Heart Failure; Humans; Hydrogen Peroxide; Interleukin-1beta; Interleukin-6; Lactate Dehydrogenases; Molecular Docking Simulation; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Superoxide Dismutase; Tumor Necrosis Factor-alpha	2022
Empagliflozin in patients hospitalized for acute heart failure. European heart journal, 2022, 11-01, Volume: 43, Issue:41 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit? European heart journal, 2022, 09-21, Volume: 43, Issue:36 Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Uric Acid	2022
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial. Circulation. Heart failure, 2022, Volume: 15, Issue:8 Topics: Benzhydryl Compounds; Biomarkers; Clinical Trials as Topic; Glucosides; Heart Failure; Humans	2022
Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure. European journal of pharmacology, 2022, Sep-15, Volume: 931 Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glucosides; Heart Failure; Male; Mice; Mitochondria; Sodium-Glucose Transporter 2 Inhibitors	2022
Dapagliflozin for patients with heart failure and reduced ejection fraction. JAAPA : official journal of the American Academy of Physician Assistants, 2022, Sep-01, Volume: 35, Issue:9 Topics: Adult; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2022
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure. European heart journal, 2022, 11-01, Volume: 43, Issue:41 Topics: Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors	2022
MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:15 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis	2022
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"]. Annales de cardiologie et d'angeiologie, 2022, Volume: 71, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Echocardiography; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Stroke Volume	2022
Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients. Disease markers, 2022, Volume: 2022 Topics: Benzhydryl Compounds; C-Reactive Protein; Cardiomyopathies; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Failure; Humans; Interleukin-6; Tumor Necrosis Factor-alpha	2022
Dapagliflozin improves outcomes in HFmrEF and HFpEF. Nature reviews. Cardiology, 2022, Volume: 19, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume; Ventricular Function, Left	2022
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovascular diabetology, 2022, 09-16, Volume: 21, Issue:1 Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Percutaneous Coronary Intervention; Prognosis; Receptors, Angiotensin; Retrospective Studies; Triglycerides	2022
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF. International journal of molecular sciences, 2022, Sep-09, Volume: 23, Issue:18 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hypoglycemic Agents; Mice; Stroke Volume	2022
Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251. Diabetes care, 2022, 10-01, Volume: 45, Issue:10 Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251. Diabetes care, 2022, 10-01, Volume: 45, Issue:10 Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin. Basic research in cardiology, 2022, 09-28, Volume: 117, Issue:1 Topics: Animals; B-Lymphocytes; Benzhydryl Compounds; Bone Marrow; Glucosides; Heart Failure; Immunoglobulin D; Immunoglobulin M; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Percutaneous Coronary Intervention; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Remodeling	2022
How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. International journal of cardiology, 2023, Jan-15, Volume: 371 Topics: Adolescent; Benzhydryl Compounds; Delivery of Health Care; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; State Medicine; Stroke Volume	2023
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status. Annals of internal medicine, 2022, Volume: 175, Issue:10 Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left	2022
Dapagliflozin Inhibits Ventricular Remodeling in Heart Failure Rats by Activating Autophagy through AMPK/mTOR Pathway. Computational and mathematical methods in medicine, 2022, Volume: 2022 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Atrial Natriuretic Factor; Autophagy; Autophagy-Related Proteins; Benzhydryl Compounds; Caspase 3; Glucosides; Heart Failure; Hypoxia; Myocytes, Cardiac; Rats; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Remodeling	2022
The position of SGLT2 inhibitors in current medical practice - update 2022. Vnitrni lekarstvi, 2022,Summer, Volume: 68, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2022
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model. International journal of molecular sciences, 2022, Sep-20, Volume: 23, Issue:19 Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Drinking Water; Glucose; Glucosides; Heart Failure; Lipids; Muscle, Skeletal; Obesity; Rats; Saponins; Sodium; Stroke Volume; Ventricular Function, Left	2022
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. PloS one, 2022, Volume: 17, Issue:10 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors	2022
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial]. Terapevticheskii arkhiv, 2021, Dec-15, Volume: 93, Issue:12 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
SGLT2 inhibitors in heart failure: insights from plasma proteomics. European heart journal, 2022, 12-21, Volume: 43, Issue:48 Topics: Glucosides; Heart Failure; Humans; Proteomics; Sodium-Glucose Transporter 2 Inhibitors	2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled. Circulation, 2023, 01-03, Volume: 147, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; White	2023
The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus. Pacing and clinical electrophysiology : PACE, 2023, Volume: 46, Issue:1 Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male	2023
Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? European heart journal, 2023, 01-01, Volume: 44, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2023
Empagliflozin benefits in patients with heart failure and preserved ejection fraction. Nature medicine, 2022, Volume: 28, Issue:12 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2022
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF). Drug and therapeutics bulletin, 2023, Volume: 61, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2023
Is Dapagliflozin a Cardiac Anti-Aging Drug? JACC. Heart failure, 2023, Volume: 11, Issue:3 Topics: Aging; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2023
Trace element equilibrium in acute heart failure and the effect of empagliflozin. European journal of heart failure, 2023, Volume: 25, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Trace Elements	2023
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:5 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents	2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 2023, 04-04, Volume: 147, Issue:14 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Proportional Hazards Models; Stroke Volume	2023
Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF". Circulation, 2023, 03-14, Volume: 147, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left	2023
Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF". Circulation, 2023, 03-14, Volume: 147, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2023
Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial". Circulation, 2023, 04-04, Volume: 147, Issue:14 Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans	2023
Using dapagliflozin in patients with heart failure. Nursing, 2023, Jun-01, Volume: 53, Issue:6 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2023
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. European heart journal, 2023, 06-25, Volume: 44, Issue:24 Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Heart Failure, Diastolic; Hospitalization; Humans; Male; Medicare; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2023
In brief: Expanded heart failure indication for dapagliflozin (Farxiga). The Medical letter on drugs and therapeutics, 2023, 06-26, Volume: 65, Issue:1679 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents	2023
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial. European journal of heart failure, 2023, Volume: 25, Issue:8 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume	2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. Journal of the American College of Cardiology, 2023, 07-11, Volume: 82, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2023
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study. Cardiovascular diabetology, 2023, 07-26, Volume: 22, Issue:1 Topics: Benzhydryl Compounds; Cohort Studies; Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2023
Topping Off the Pill Box: Dapagliflozin, Heart Failure, and Polypharmacy. JACC. Heart failure, 2023, Volume: 11, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Polypharmacy; Stroke Volume; Ventricular Function, Left	2023
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations. Annals of internal medicine, 2023, Volume: 176, Issue:9 Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic	2023
Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories. Journal of the American College of Cardiology, 2023, 10-10, Volume: 82, Issue:15 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Stroke Volume	2023
Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice. Scientific reports, 2023, 10-21, Volume: 13, Issue:1 Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Homeostasis; Humans; Mice; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha	2023
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular diabetology, 2019, 08-20, Volume: 18, Issue:1 Topics: Animals; Aorta; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytokines; Disease Models, Animal; Female; Fibrosis; Glucosides; Heart Failure; Hypertension; Inflammation Mediators; Lipids; Nitric Oxide; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Sus scrofa; Sympathetic Nervous System; Ventricular Function, Left; Ventricular Remodeling	2019
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 11-05, Volume: 140, Issue:19 Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Heart-Failure Therapy - New Drugs but Old Habits? The New England journal of medicine, 2019, 11-21, Volume: 381, Issue:21 Topics: Benzhydryl Compounds; Glucosides; Habits; Heart Failure; Humans; Stroke Volume	2019
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF. Nature reviews. Cardiology, 2019, Volume: 16, Issue:12 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2019
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovascular diabetology, 2019, 10-04, Volume: 18, Issue:1 Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". Circulation, 2019, 10-29, Volume: 140, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2019
Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". Circulation, 2019, 10-29, Volume: 140, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2019
SGLT-2 inhibitors in heart failure: a new therapeutic avenue. Nature medicine, 2019, Volume: 25, Issue:11 Topics: Benzhydryl Compounds; Death, Sudden, Cardiac; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2019
Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. Circulation, 2020, 01-14, Volume: 141, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2020
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. European journal of pharmacology, 2020, Jan-05, Volume: 866 Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Disease Models, Animal; Fatty Acids; Glucosides; Heart Failure; Insulin; Male; Mice; Mice, Inbred C57BL; Mitochondria; Muscle Strength; Muscle, Skeletal; Oxidation-Reduction; Oxidative Phosphorylation; Physical Conditioning, Animal; Physical Endurance; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors	2020
Dapagliflozin in heart failure: new frontiers. European journal of heart failure, 2019, Volume: 21, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2019
Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice. Journal of pharmacological sciences, 2020, Volume: 142, Issue:1 Topics: Animals; Fibrosis; Gene Expression Regulation; Glucosides; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Pyrazoles; RNA, Messenger; Sodium-Glucose Transporter 1; Ventricular Remodeling	2020
Dapagliflozin for HFrEF - improved outcomes across all ages. Nature reviews. Cardiology, 2020, Volume: 17, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2020
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. European journal of heart failure, 2020, Volume: 22, Issue:2 Topics: Benzhydryl Compounds; Canagliflozin; Cardiology; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors	2020
Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. European journal of heart failure, 2020, Volume: 22, Issue:1 Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2020
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction. Cardiovascular research, 2020, 01-01, Volume: 116, Issue:1 Topics: Benzhydryl Compounds; Disease Progression; Glucosides; Heart Failure; Humans; Incidence; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left	2020
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovascular diabetology, 2020, 01-07, Volume: 19, Issue:1 Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Japan; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2020
La Revue de medecine interne, 2020, Volume: 41, Issue:2 Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left	2020
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circulation. Heart failure, 2020, Volume: 13, Issue:1 Topics: Animals; Benzhydryl Compounds; Carrier Proteins; Glucosides; Heart Diseases; Heart Failure; Inflammasomes; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Stroke Volume	2020
Dapagliflozin Cut Risk of Worsening Heart Failure. JAMA, 2020, Jan-28, Volume: 323, Issue:4 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovascular diabetology, 2020, 02-08, Volume: 19, Issue:1 Topics: Animals; Benzhydryl Compounds; Calcium Signaling; Disease Models, Animal; Glucosides; Heart Failure; Myocardial Infarction; Myocardium; Rats, Inbred F344; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left; Ventricular Pressure	2020
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fraction. Annals of internal medicine, 2020, 02-18, Volume: 172, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2020
Sodium-glucose co-transporter 2 inhibitors and acute heart failure. European journal of heart failure, 2020, Volume: 22, Issue:4 Topics: Benzhydryl Compounds; Double-Blind Method; Glucose; Glucosides; Heart Failure; Humans; Pilot Projects; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2020
Dapagliflozin in patients with heart failure and reduced ejection fraction. Internal and emergency medicine, 2020, Volume: 15, Issue:3 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires	2020
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2020
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2020
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2020
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left	2020
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions. Cardiovascular diabetology, 2020, 03-10, Volume: 19, Issue:1 Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
A Novel Cardioprotective Therapy That Also Improves Glycemia. JAMA, 2020, 04-14, Volume: 323, Issue:14 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Glucosides; Heart Failure; Humans	2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European heart journal, 2020, 07-01, Volume: 41, Issue:25 Topics: Angiotensin Receptor Antagonists; Benzhydryl Compounds; Diuretics; Glucosides; Heart Failure; Humans	2020
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus. Heart and vessels, 2020, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuresis; Natriuretic Agents; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome	2020
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2020, Volume: 48, Issue:3 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Diuresis; Female; Glucosides; Glycosuria; Heart Failure; Heart Ventricles; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Myocardium; Natriuresis; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Walk Test	2020
Prognosis of patients eligible for dapagliflozin in acute heart failure. European journal of clinical investigation, 2020, Volume: 50, Issue:6 Topics: Acute Disease; Aged; Aged, 80 and over; Benzhydryl Compounds; Cause of Death; Cohort Studies; Eligibility Determination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Patient Readmission; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care. European heart journal, 2020, 07-01, Volume: 41, Issue:25 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Motivation; Sodium-Glucose Transporter 2 Inhibitors; Standard of Care; Stroke Volume	2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. American journal of hypertension, 2020, 12-31, Volume: 33, Issue:12 Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome	2020
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:9 Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left	2020
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovascular research, 2021, 01-21, Volume: 117, Issue:2 Topics: Aged; Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Cyclic GMP-Dependent Protein Kinase Type I; Disease Models, Animal; Endothelial Cells; Female; Glucosides; Heart Failure; Humans; Inflammation Mediators; Male; Middle Aged; Myocytes, Cardiac; Oxidative Stress; Rats, Zucker; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2021
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clinical drug investigation, 2020, Volume: 40, Issue:7 Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2020
[Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus]. Kardiologiia, 2020, Jun-03, Volume: 60, Issue:5 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome	2020
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovascular diabetology, 2020, 06-22, Volume: 19, Issue:1 Topics: Adult; Aged; Benzhydryl Compounds; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Female; Glucosides; Heart Failure; Hospital Costs; Humans; Incidence; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2020
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Journal of hypertension, 2020, Volume: 38, Issue:9 Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors	2020
Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction? Cardiovascular research, 2021, 01-21, Volume: 117, Issue:2 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocytes, Cardiac; Oxidative Stress; Protein Kinases; Stroke Volume	2021
SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure. Cell metabolism, 2020, 07-07, Volume: 32, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2020
Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure. American family physician, 2020, 07-15, Volume: 102, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers, Pharmacological; Drugs, Investigational; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States	2020
Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert review of cardiovascular therapy, 2020, Volume: 18, Issue:9 Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocardial Infarction; Myocardium; Sodium-Glucose Transporter 2 Inhibitors; Swine; Ventricular Function, Left	2020
Dapagliflozin (Farxiga) - a new indication for heart failure. The Medical letter on drugs and therapeutics, 2020, Jun-29, Volume: 62, Issue:1601 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2020
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European journal of heart failure, 2020, Volume: 22, Issue:11 Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Female; Germany; Glucosides; Heart Failure; Humans; Male; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Spain; Ventricular Function, Left	2020
Dapagliflozin for heart failure: is it a class effect? Future cardiology, 2021, Volume: 17, Issue:2 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2021
Quadruple Therapy Is the New Standard of Care for HFrEF. JACC. Heart failure, 2020, Volume: 8, Issue:10 Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Standard of Care; Stroke Volume; Tetrazoles; Valsartan	2020
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International journal of cardiology, 2021, 01-01, Volume: 322 Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume; Thailand; Ventricular Function, Left	2021
Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis. PLoS computational biology, 2020, Volume: 16, Issue:8 Topics: Benzhydryl Compounds; Cardiomegaly; Extracellular Fluid; Glucosides; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Models, Cardiovascular; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2020
Pharmacology Focus: Dapagliflozin Use in Reduced Ejection Fraction Heart Failure. South Dakota medicine : the journal of the South Dakota State Medical Association, 2020, Volume: 73, Issue:7 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume	2020
DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction? European journal of heart failure, 2020, Volume: 22, Issue:11 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume	2020
Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes. Scientific reports, 2020, 08-20, Volume: 10, Issue:1 Topics: Animals; Benzhydryl Compounds; C-Peptide; Cardiotonic Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Heart Failure; Humans; Hyperinsulinism; Hypertension; Male; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sodium-Glucose Transporter 2 Inhibitors	2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European heart journal, 2020, 09-21, Volume: 41, Issue:36 Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left	2020
Antihyperglycemic Drug Approved to Treat Heart Failure. The American journal of nursing, 2020, Volume: 120, Issue:9 Topics: Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Stroke Volume; United States; United States Food and Drug Administration	2020
More Evidence for SGLT2 Inhibitors in Heart Failure. The New England journal of medicine, 2020, 10-08, Volume: 383, Issue:15 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2020
Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert review of cardiovascular therapy, 2020, Volume: 18, Issue:11 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Remodeling	2020
The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. European heart journal, 2020, 09-21, Volume: 41, Issue:36 Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans	2020
Empagliflozin improves outcomes in HFrEF regardless of diabetic status. Nature reviews. Cardiology, 2020, Volume: 17, Issue:11 Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Heart Failure; Humans; Stroke Volume	2020
Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:21 Topics: Animals; Benzhydryl Compounds; Biopsy; Cell Survival; Cellular Senescence; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucosides; Heart; Heart Failure; Inflammation; Male; Mice; Mice, Inbred C57BL; Myocardium; Sodium-Glucose Transporter 2; Stromal Cells; Ventricular Function, Left	2020
Evaluation of dapagliflozin in the treatment of heart failure. Future cardiology, 2021, Volume: 17, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2021
EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. European heart journal, 2020, 10-21, Volume: 41, Issue:40 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation, 2021, 01-26, Volume: 143, Issue:4 Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD. Kidney international, 2020, Volume: 98, Issue:6 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2020
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology, 2021, Volume: 61, Issue:5 Topics: Benzhydryl Compounds; Blood Glucose; Blood Volume; Computer Simulation; Diabetes Mellitus, Type 2; Diuresis; Glomerular Filtration Barrier; Glucosides; Heart Failure; Hematocrit; Hemodynamics; Humans; Models, Theoretical; Natriuresis; Sodium-Glucose Transporter 2 Inhibitors	2021
Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert review of cardiovascular therapy, 2021, Volume: 19, Issue:1 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Remodeling	2021
Current and Emerging Issues in the Management of Heart Failure in Primary Care. The Journal of family practice, 2020, Volume: 69, Issue:7 Suppl Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors	2020
Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function. JACC. Cardiovascular imaging, 2021, Volume: 14, Issue:2 Topics: Benzhydryl Compounds; Fibrosis; Glucosides; Heart Failure; Humans; Predictive Value of Tests; Sodium-Glucose Transporter 2	2021
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC. Cardiovascular imaging, 2021, Volume: 14, Issue:2 Topics: Animals; Benzhydryl Compounds; Diastole; Fibrosis; Glucosides; Heart Failure; Heart Ventricles; Predictive Value of Tests; Stroke Volume; Swine; Ventricular Dysfunction, Left; Ventricular Function, Left	2021
Organ protection beyond glycaemic control with SGLT2 inhibitors. Nature reviews. Nephrology, 2021, Volume: 17, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Glycemic Control; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. Circulation. Heart failure, 2020, Volume: 13, Issue:12 Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation, 2021, 01-26, Volume: 143, Issue:4 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. Annals of internal medicine, 2020, 11-17, Volume: 173, Issue:10 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans	2020
Understanding the Mechanistic Benefit of Heart Failure Drugs Matters. Journal of the American College of Cardiology, 2020, 12-08, Volume: 76, Issue:23 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Pharmaceutical Preparations; Stroke Volume	2020
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF? JACC. Heart failure, 2020, Volume: 8, Issue:12 Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan	2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes care, 2021, Volume: 44, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Incidence; Stroke Volume	2021
SGLT2 inhibitors: expanding their Empire beyond diabetes. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors	2021
EMPEROR-REDUCED reigns while EMPERIAL whimpers. European heart journal, 2021, 02-11, Volume: 42, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume	2021
Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic. European journal of heart failure, 2021, Volume: 23, Issue:1 Topics: Benzhydryl Compounds; Diuretics, Osmotic; Glucosides; Heart Failure; Humans; Sodium	2021
Highlights from the European society of cardiology congress 2020. Journal of thrombosis and thrombolysis, 2021, Volume: 51, Issue:1 Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Coronary Artery Disease; Europe; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors; Tubulin Modulators; Uracil	2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European heart journal, 2021, 03-31, Volume: 42, Issue:13 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume	2021
Empagliflozin (Jardiance) for heart failure. The Medical letter on drugs and therapeutics, 2020, 11-16, Volume: 62, Issue:1611 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2020
Heart failure drug treatment: the fantastic four. European heart journal, 2021, 02-11, Volume: 42, Issue:6 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Neprilysin; Pharmaceutical Preparations	2021
Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure. Circulation, 2021, 01-26, Volume: 143, Issue:4 Topics: Diabetes Mellitus, Type 2; Diamond; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Empagliflozin in Heart Failure. Reply. The New England journal of medicine, 2021, 01-28, Volume: 384, Issue:4 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible? Cardiology, 2021, Volume: 146, Issue:2 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Ventricular Function, Left	2021
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Endocrinology, diabetes & metabolism, 2021, Volume: 4, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia, Eastern; Benzhydryl Compounds; Data Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Risk; Treatment Outcome; Young Adult	2021
Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care. European heart journal, 2021, 03-31, Volume: 42, Issue:13 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Patient-Centered Care; Quality of Life	2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. European journal of preventive cardiology, 2021, 12-29, Volume: 28, Issue:15 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan	2021
Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiologia polska, 2021, 03-25, Volume: 79, Issue:3 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Expert Testimony; Female; Glucosides; Heart Failure; Humans; Male; Poland; Quality of Life; Stroke Volume; Ventricular Function, Left	2021
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:5 Topics: Benzhydryl Compounds; Glucosides; Health Policy; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United Kingdom	2021
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure. Journal of the American Heart Association, 2021, 03-16, Volume: 10, Issue:6 Topics: Animals; Benzhydryl Compounds; Blood Pressure; Disease Models, Animal; Echocardiography; Glucosides; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Phosphorylation; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left	2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 05-18, Volume: 143, Issue:20 Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors	2021
Fluid volume regulation in patients with heart failure. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:5 Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume	2021
Fluid volume regulation in patients with heart failure. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:5 Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume	2021
Fluid volume regulation in patients with heart failure - Authors' reply. The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:5 Topics: Benzhydryl Compounds; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Plasma Volume	2021
Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:4 Topics: Animals; Benzhydryl Compounds; Glucosides; Heart Failure; Hypertrophy, Left Ventricular; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Sodium-Glucose Transporter 2; TWEAK Receptor; Ventricular Remodeling	2022
Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European journal of heart failure, 2021, Volume: 23, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Potassium; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2021
Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial". American heart journal, 2021, Volume: 236 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. The American journal of cardiology, 2021, 07-01, Volume: 150 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Primary Prevention; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2021
Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA cardiology, 2021, 08-01, Volume: 6, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans	2021
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA cardiology, 2021, 08-01, Volume: 6, Issue:8 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2021
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status. Annals of internal medicine, 2021, Volume: 174, Issue:6 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume	2021
Efficacy and safety of dapagliflozin in the treatment of chronic heart failure: A protocol for systematic review and meta-analysis. Medicine, 2021, Jul-02, Volume: 100, Issue:26 Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Treatment Outcome	2021
Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. International journal of cardiology, 2021, 09-15, Volume: 339 Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies	2021
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 2021, 07-20, Volume: 144, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume	2021
Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 2021, 07-20, Volume: 144, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume	2021
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland. International journal of molecular sciences, 2021, Jul-19, Volume: 22, Issue:14 Topics: Adrenal Glands; Animals; Benzhydryl Compounds; Cardiovascular Agents; Catecholamines; Glucosides; Heart Failure; Humans; Ketone Bodies; Models, Biological; Receptors, G-Protein-Coupled; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Structure-Activity Relationship; Sympatholytics	2021
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA network open, 2021, 07-01, Volume: 4, Issue:7 Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires	2021
Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection? JACC. Heart failure, 2021, Volume: 9, Issue:8 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Myocardium	2021
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:15 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2021
Is Dapagliflozin Cost-effective for Treating Heart Failure? JAMA, 2021, Aug-03, Volume: 326, Issue:5 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors	2021
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 2021, 10-12, Volume: 144, Issue:15 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Kidney	2021
Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. European journal of preventive cardiology, 2021, 08-09, Volume: 28, Issue:9 Topics: Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Glucosides; Heart Failure; Humans	2021
The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. European journal of heart failure, 2021, Volume: 23, Issue:10 Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Heart Failure, Systolic; Humans; Obesity; Prognosis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2021
Antidiabetic Drug Approved to Reduce Risk of Kidney Disease. The American journal of nursing, 2021, 09-01, Volume: 121, Issue:9 Topics: Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Time Factors	2021
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database. The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left	2017
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Molecular and cellular biochemistry, 2017, Volume: 433, Issue:1-2 Topics: Animals; Animals, Genetically Modified; Aristolochic Acids; Benzhydryl Compounds; Biomarkers; Clinical Trials as Topic; Disease Models, Animal; Female; Glucosides; Heart Failure; Humans; Male; Zebrafish	2017
Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus - Is it empaglifozin or the class? Journal of diabetes and its complications, 2017, Volume: 31, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2017
Introduction. The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke	2017
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA cardiology, 2017, 09-01, Volume: 2, Issue:9 Topics: Benzhydryl Compounds; Blood Vessels; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Kidney Tubules, Proximal; Myocardium; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchangers	2017
Empagliflozin across the stages of diabetic heart disease. European heart journal, 2018, 02-01, Volume: 39, Issue:5 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans	2018
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug discoveries & therapeutics, 2018, Mar-19, Volume: 12, Issue:1 Topics: Aged, 80 and over; Body Weight; Glucosides; Heart Failure; Hospitalization; Humans; Male; Myocardial Perfusion Imaging; Sympathetic Nervous System; Thiophenes; Treatment Outcome	2018
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? Current vascular pharmacology, 2019, Volume: 17, Issue:4 Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Resistance; Glucosides; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Water-Electrolyte Balance	2019
Empagliflozin directly improves diastolic function in human heart failure. European journal of heart failure, 2018, Volume: 20, Issue:12 Topics: Animals; Benzhydryl Compounds; Biopsy; Diastole; Disease Models, Animal; Echocardiography; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Mice; Middle Aged; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Rats; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left	2018
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European journal of heart failure, 2019, Volume: 21, Issue:3 Topics: Benzhydryl Compounds; Cardiotonic Agents; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 03-12, Volume: 139, Issue:11 Topics: Benzhydryl Compounds; Cause of Death; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. Circulation, 2019, 05-28, Volume: 139, Issue:22 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors	2019
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovascular diabetology, 2019, 04-01, Volume: 18, Issue:1 Topics: Animals; Atrial Function, Left; Atrial Natriuretic Factor; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fibrosis; Gene Expression Regulation; Glucosides; Heart Failure; Hemodynamics; Hypertension; Male; Myocardium; Natriuretic Peptide, Brain; Rats, Inbred SHR; Rats, Inbred WKY; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling	2019
Stratifying the effects of SGLT2i. Nature reviews. Cardiology, 2019, Volume: 16, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans	2019
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation, 2019, 06-18, Volume: 139, Issue:25 Topics: Aged; Benzhydryl Compounds; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; United States	2019
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 2019, 04-23, Volume: 73, Issue:15 Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Diabetes Mellitus; Disease Models, Animal; Echocardiography, Three-Dimensional; Glucosides; Heart Failure; Heart Function Tests; Random Allocation; Reference Values; Sodium-Glucose Transporter 2 Inhibitors; Statistics, Nonparametric; Stroke Volume; Swine; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling	2019
SGLT2 Inhibition: Changing What Fuels the Heart. Journal of the American College of Cardiology, 2019, 04-23, Volume: 73, Issue:15 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Ventricular Remodeling	2019
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 09-01, Volume: 35, Issue:9 Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2020
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. European journal of heart failure, 2019, Volume: 21, Issue:7 Topics: Animals; Benzhydryl Compounds; Echocardiography; Energy Metabolism; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2019
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community. Cardiovascular research, 2019, 05-01, Volume: 115, Issue:6 Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes. European journal of heart failure, 2019, Volume: 21, Issue:7 Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left	2019
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circulation. Heart failure, 2019, Volume: 12, Issue:6 Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2019
Empagliflozin and Heart Failure. Circulation, 2019, 06-18, Volume: 139, Issue:25 Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans	2019
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Circulation, 2019, 08-06, Volume: 140, Issue:6 Topics: Benzhydryl Compounds; Blood Volume; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics; Glucose; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Multicenter Studies as Topic; Myocardial Infarction; Natriuresis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stroke; Stroke Volume	2019
The energy metabolism of the failing heart and the metabolic action of the cardiac glycosides. Pharmacological reviews, 1949, Volume: 1, Issue:3 Topics: Cardiac Glycosides; Energy Metabolism; Glucosides; Heart; Heart Failure; Humans	1949
Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure. International journal of cardiology, 2015, Feb-01, Volume: 180 Topics: Diabetes Mellitus; Diuresis; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Thiophenes	2015
Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models. European journal of pharmacology, 2015, Jan-05, Volume: 746 Topics: Adrenergic alpha-1 Receptor Agonists; Animals; Animals, Newborn; Atrial Natriuretic Factor; Cardiomegaly; Cardiotonic Agents; Cell Size; Cells, Cultured; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; Heart Failure; Heart Ventricles; Male; Mice, Inbred C57BL; Oxidative Stress; Phenylephrine; Rats; rho-Associated Kinases; Stilbenes; Ventricular Remodeling	2015
Response to the letter by Akinori Sairaku et al.: Different mechanisms = synergic effect. International journal of cardiology, 2015, May-01, Volume: 186 Topics: Diuresis; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Stroke Volume; Thiophenes	2015
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2015
Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus. Journal of diabetes and its complications, 2016, Volume: 30, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis	2016
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. Revue medicale de Liege, 2015, Volume: 70, Issue:11 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic	2015
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney international, 2016, Volume: 89, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Natriuresis; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
[Empagliflozin reduces heart failure risk by a third]. MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Heart Failure; Humans; Outcome Assessment, Health Care; Risk; Survival Rate	2015
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. Circulation, 2016, 12-13, Volume: 134, Issue:24 Topics: Benzhydryl Compounds; Cardiologists; Clinical Decision-Making; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Patient Selection; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. Journal of diabetes and its complications, 2017, Volume: 31, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins	2017
Functional effects of glucose transporters in human ventricular myocardium. European journal of heart failure, 2010, Volume: 12, Issue:2 Topics: Aged; Carbonates; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Glucose Transporter Type 1; Glucose Transporter Type 4; Glucosides; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Inhibitory Concentration 50; Insulin; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardium; Phosphoinositide-3 Kinase Inhibitors; RNA, Messenger; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2010
[The use of Convallaria glucosides in the therapy of myocardial decompensation]. Gazzetta medica italiana, 1953, Volume: 112, Issue:10 Topics: Convallaria; Glucosides; Heart Failure	1953
[New associations of digitalis (d.purpurea) glucosides]. Il Policlinico. Sezione pratica, 1954, May-31, Volume: 61, Issue:22 Topics: Digitalis; Digitalis Glycosides; Glucosides; Heart Failure; Humans; Plant Extracts	1954
[Practical aspects of glucoside therapy in cardiac insufficiency]. Klinicheskaia meditsina, 1957, Volume: 35, Issue:3 Topics: Cardiac Glycosides; Glucosides; Heart Failure; Humans	1957
[INFLUENCE OF CARDIOTONIC GLUCOSIDES ON THE INTERMEDIATE METABOLISM OF THE MYOCARDIUM]. Acta clinica Belgica, 1963, Volume: 18 Topics: Adenosine Triphosphatases; Cardiotonic Agents; Digitalis Glycosides; Glucosides; Heart Failure; Humans; Metabolism; Myocardium; Phosphates; Proteins	1963
[Allergy to k-strophanthoside and other cardiokinetic glucosides; considerations on the dangers of intolerance of allergic types to drugs in general]. L' Ospedale maggiore, 1954, Volume: 42, Issue:10 Topics: Glucosides; Heart Failure; Hypersensitivity; Immune System Diseases; Strophanthins	1954
[Therapy of heart failure with digitalis glucosides]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1950, Sep-02, Volume: 26, Issue:65 Topics: Digitalis; Digitalis Glycosides; Glucosides; Heart Failure; Plant Extracts	1950
[Therapeutic value of a glucoside extracted from oleander]. Archives des maladies du coeur et des vaisseaux, 1950, Volume: 43, Issue:12 Topics: Glucosides; Heart Failure; Humans; Nerium	1950